-DOCSTART- -X- N

atrial JJ Condition
fibrillation NN Condition
. . None
nonvalvular JJ Condition
atrial JJ Condition
fibrillation NN Condition
patients NNS None
using VBG None
2 CD None
different JJ None
elicitation NN None
methods NNS None
. . None
practices NNS None
of IN None
2 CD None
university-affiliated JJ None
family NN None
medicine NN None
centers NNS None
( ( None
8 CD None
physicians NNS None
each DT None
) ) None
, , None
14 CD None
community-based JJ None
family NN None
physicians NNS None
, , None
and CC None
2 CD None
cardiologists NNS None
. . None
Sixty-four JJ Size
patients NNS None
with IN None
nonvalvular JJ Condition
atrial JJ Condition
fibrillation NN Condition
who WP None
were VBD None
initiated VBN None
with IN None
warfarin JJ None
therapy NN None
at IN None
least JJS None
3 CD None
months NNS None
before IN None
the DT None
study NN None
. . None
patients NNS None
with IN None
nonvalvular JJ Condition
atrial JJ Condition
fibrillation NN Condition
. . None
-DOCSTART- -X- N

able-bodied JJ None
participants NNS None
. . None
Participants NNS None
( ( None
n=14 CC None
) ) None
and CC None
a DT None
control NN None
group NN None
( ( None
n=7 RB None
) ) None
. . None
able-bodied JJ None
participants NNS None
. . None
-DOCSTART- -X- N

One CD None
hundred VBD None
forty-two JJ None
patients NNS None
-DOCSTART- -X- N

76 CD Size
patients NNS None
undergoing JJ None
primary JJ Condition
total JJ Condition
knee NN Condition
arthroplasty NN Condition
were VBD None
assigned VBN None
-DOCSTART- -X- N

broiler NN Condition
chickens NNS Condition
during IN None
the DT None
starting NN None
and CC None
growing/finishing NN None
phases NNS None
. . None
at IN None
least JJS None
4 CD None
replicates NNS None
per IN None
treatment NN None
( ( None
50 CD Size
chicks NNS None
per IN None
replicate NN None
) ) None
were VBD None
used VBN None
. . None
Corn-soybean-meal-and JJ None
soybean-oil-based JJ None
diets NNS None
were VBD None
fed VBN None
and CC None
birds NNS None
were VBD None
raised VBN None
in IN None
a DT None
house NN None
impervious JJ None
to TO None
ultraviolet VB None
light NN None
. . None
birds NNS None
in IN None
experiment JJ None
1 CD None
. . None
birds NNS None
in IN None
experiment JJ None
1 CD None
-DOCSTART- -X- N

following VBG None
appendicectomy NN Condition
: : None
following VBG None
appendicectomy NN Condition
. . None
Consecutive JJ None
patients NNS None
undergoing VBG None
emergency NN None
appendicectomy NN Condition
postappendicectomy NN Condition
patient NN None
-DOCSTART- -X- N

17 CD Size
patients NNS None
with IN None
AS NNP Condition
( ( None
ICD-10 NNP None
; : None
14 CD Size
male NN Sex
, , None
3 CD Size
female NN Sex
; : None
mean JJ None
age NN None
16.4 CD Age
years NNS None
, , None
mean JJ None
full-scale JJ None
IQ NNP None
97 CD None
) ) None
compared VBN None
them PRP None
with IN None
a DT None
control NN None
group NN None
of IN None
13 CD Size
patients NNS None
with IN None
normal-intelligence JJ Condition
autism NN Condition
or CC None
high-functioning JJ Condition
autism NN Condition
( ( None
HFA NNP Condition
) ) None
( ( None
ICD-10/DSM-III-R NNP None
; : None
12 CD Size
male NN Sex
, , None
1 CD Size
female NN Sex
; : None
mean JJ None
age NN None
15.5 CD Age
years NNS None
, , None
mean JJ None
full-scale JJ None
IQ NNP None
81.2 CD None
) ) None
. . None
13 CD None
( ( None
76 CD None
% NN None
) ) None
of IN None
the DT None
AS NNP Condition
patients NNS None
4 CD None
( ( None
31 CD None
% NN None
) ) None
of IN None
the DT None
HFA NNP Condition
group NN None
-DOCSTART- -X- N

infants NNS None
at IN None
risk NN None
of IN None
allergic JJ None
disease NN None
. . None
Sixty-one JJ None
mother-infant JJ None
pairs NNS None
were VBD None
included VBN None
, , None
special JJ None
emphasis NN None
being VBG None
placed VBN None
on IN None
the DT None
maternal JJ None
allergic NN None
status NN None
. . None
infants NNS None
of IN None
allergic NN None
, , None
atopic NN None
mothers NNS None
Allergic NNP None
mothers NNS None
-DOCSTART- -X- N

20 CD Size
patients NNS None
with IN None
leukaemia JJ Condition
receiving VBG None
human JJ None
recombinant JJ None
granulocyte NN None
macrophage NN None
colony NN None
stimulating VBG None
factor NN None
( ( None
GM NNP None
CSF NNP None
) ) None
, , None
with IN None
20 CD Size
patients NNS None
receiving VBG None
placebo NN None
both DT None
patient JJ None
groups NNS None
. . None
-DOCSTART- -X- N

skin NN Condition
cancer NN Condition
prevention NN None
for IN None
children NNS Age
: : None
family NN None
study NN None
. . None
parents NNS Age
and CC None
their PRP$ None
children NNS None
Families NNS None
were VBD None
recruited VBN None
through IN None
schools NNS None
and CC None
community NN None
centers NNS None
and CC None
were VBD None
included VBN None
if IN None
there EX None
was VBD None
1 CD None
child NN None
in IN None
Grades NNP None
1-3 JJ None
at IN None
moderate JJ None
to TO None
high JJ None
risk NN None
for IN None
skin JJ None
cancer NN None
. . None
tailored JJ None
intervention NN None
, , None
in IN None
which WDT None
they PRP None
received VBD None
personalized JJ None
skin NN None
cancer NN None
education NN None
through IN None
the DT None
mail NN None
; : None
or CC None
a DT None
control NN None
group NN None
who WP None
received VBD None
generic JJ None
skin NN None
cancer NN None
information NN None
materials NNS None
. . None
Parents NNS None
Tailored VBN None
group NN None
participants NNS None
families NNS None
skin JJ None
cancer NN None
prevention NN None
practices NNS None
in IN None
young JJ Age
children NNS None
. . None
-DOCSTART- -X- N

competitive JJ None
athletes NNS None
Twenty NNP None
young JJ None
, , None
active JJ None
men NNS None
( ( None
mean JJ None
age NN None
26.2 CD None
? . None
2.1 CD None
years NNS None
) ) None
-DOCSTART- -X- N

practice NN None
nurses NNS None
: : None
Practice NNP None
nurses NNS None
nurses NNS None
This DT None
study NN None
was VBD None
nested VBN None
in IN None
the DT None
IMPALA NNP None
study NN None
, , None
a DT None
clustered VBN None
randomised VBN None
controlled VBN None
trial NN None
involving VBG None
24 CD None
general JJ None
practices NNS None
in IN None
The DT None
Netherlands NNP None
. . None
24 CD None
practice NN None
nurses NNS None
, , None
trained VBN None
in IN None
10-year JJ None
cardiovascular JJ None
risk NN None
assessment NN None
421 CD None
patients NNS None
without IN None
established VBN None
cardiovascular JJ None
diseases NNS None
but CC None
eligible JJ None
for IN None
cardiovascular JJ None
risk NN None
assessment NN None
. . None
Elderly JJ None
patients NNS None
male JJ None
patients NNS None
( ( None
vs. FW None
female NN None
smoking NN None
patients NNS None
( ( None
vs. IN None
non-smoking NN None
Ten NNP None
( ( None
28 CD None
% NN None
) ) None
of IN None
the DT None
36 CD None
patients NNS None
who WP None
should MD None
be VB None
assigned VBN None
to TO None
the DT None
high-risk JJ None
treatment NN None
category NN None
trained JJ None
practice NN None
nurses NNS None
in IN None
actual JJ None
practice NN None
nurses NNS None
in IN None
general JJ None
practice NN None
-DOCSTART- -X- N

healthy JJ Condition
subjects NNS None
. . None
12 CD Size
healthy JJ Condition
male NN Sex
volunteers NNS None
Six CD Size
subjects NNS None
fasted VBN None
conditions NNS None
from IN None
days NNS None
1 CD None
to TO None
6 CD None
and CC None
then RB None
crossed VBD None
over IN None
to TO None
fed VB None
conditions NNS None
from IN None
days NNS None
7 CD None
to TO None
12 CD None
. . None
six CD Size
subjects NNS None
fed VBN None
for IN None
days NNS None
1-6 CD None
and CC None
fasted VBN None
for IN None
days NNS None
7-12 CD None
-DOCSTART- -X- N

apical JJ None
hypertrophic JJ None
cardiomyopathy NN None
: : None
Thirteen JJ None
patients NNS None
who WP None
had VBD None
predominant JJ None
hypertrophy NN None
( ( None
> CD None
or CC None
= VB None
15 CD None
mm NN None
) ) None
at IN None
the DT None
apical JJ None
level NN None
without IN None
the DT None
spadelike NN None
configuration NN None
underwent JJ None
NMR NNP None
imaging VBG None
twice RB None
before RB None
and CC None
after IN None
54+/-10 JJ None
months NNS None
' POS None
follow-up NN None
. . None
-DOCSTART- -X- N

Third- JJ Age
and CC Age
fourth-grade JJ Age
students NNS Age
in IN None
a DT None
comparing NN None
symbols NNS None
group NN None
-DOCSTART- -X- N

post-tonsillectomy NN None
. . None
Thirty-seven JJ None
patients NNS None
from IN None
5 CD None
to TO None
14 CD None
years NNS None
old JJ None
undergoing JJ None
electrocautery NN None
tonsillectomy NN None
mouth NN None
rinse NN None
water NN None
rinse NN None
( ( None
control NN None
) ) None
treatment NN None
group NN None
control NN None
group NN None
. . None
-DOCSTART- -X- N

stable JJ Condition
angina NN Condition
of IN Condition
effort NN Condition
26 CD Size
patients NNS None
with IN None
stable JJ Condition
exertional JJ Condition
angina NN Condition
pectoris NN Condition
angina NN Condition
-DOCSTART- -X- N

older JJR None
patients NNS None
with IN None
diabetes NNS Condition
: : None
elderly JJ Age
patients NNS None
patients NNS None
with IN None
diabetes NNS Condition
. . None
elderly JJ None
patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
. . None
Eleven NNP Size
thousand VBP Size
one CD Size
hundred CD Size
and CC Size
forty JJ Size
patients NNS None
aged VBN None
at IN None
least JJS None
55 CD Age
years NNS None
with IN None
type NN None
2 CD None
diabetes NNS None
( ( None
mean JJ None
66+/-6 CD Age
years NNS None
) ) None
subgroups NNS None
according VBG None
to TO None
age NN None
: : None
below IN Age
65 CD Age
, , None
65-74 JJ Age
and CC None
at IN Age
least JJS Age
75 CD Age
years NNS Age
. . None
patients NNS None
of IN None
at IN None
least JJS None
75 CD None
years NNS None
with IN None
type NN None
2 CD None
diabetes NNS None
. . None
older JJR None
patients NNS None
in IN None
this DT None
age NN None
group NN None
-DOCSTART- -X- N

borderline JJ None
hypertensive JJ None
patients NNS None
with IN None
IDDM-type NNP None
diabetes NNS None
mellitus NN None
Twenty-nine JJ None
IDDM NNP None
patients NNS None
with IN None
borderline JJ None
hypertension NN None
diabetic JJ None
patients NNS None
with IN None
borderline JJ None
hypertension NN None
-DOCSTART- -X- N

patients NNS None
undergoing VBG None
isolated JJ Condition
limb NN Condition
perfusion NN Condition
with IN None
high-dose JJ None
tumor NN None
necrosis NN None
factor NN None
, , None
interferon NN None
gamma NN None
, , None
and CC None
melphalan NN None
. . None
Nineteen NNP Size
patients NNS None
with IN None
extremity NN Condition
melanoma NN Condition
( ( None
n JJ None
= NNP None
16 CD Size
) ) None
or CC None
sarcoma NN Condition
( ( None
n JJ None
= NNP None
3 CD Size
) ) None
-DOCSTART- -X- N

Bitewing NNP None
film NN None
quality NN None
: : None
Four NNP None
bitewing VBG None
films NNS None
right NN None
and CC None
left VBD None
premolar JJ None
and CC None
molar JJ None
regions NNS None
of IN None
45 CD Size
dental JJ None
students NNS None
360 CD None
films NNS None
-DOCSTART- -X- N

drug NN None
therapy NN None
of IN None
myocardial JJ Condition
ischemia NN Condition
during IN None
the DT None
peri-PTCA JJ Condition
period NN None
. . None
peri-PTCA JJ Condition
( ( None
percutaneous JJ Condition
transluminal JJ Condition
coronary JJ Condition
angioplasty NN Condition
) ) None
30 CD Size
patients NNS None
. . None
30 CD Size
patients NNS None
. . None
-DOCSTART- -X- N

sublingual JJ Condition
and CC Condition
vaginal JJ Condition
misoprostol NN Condition
in IN Condition
second JJ Condition
trimester NN Condition
termination NN Condition
of IN Condition
pregnancy NN Condition
. . Condition
second JJ None
trimester NN None
medical JJ None
abortion NN None
. . None
Tertiary JJ None
referral JJ None
unit NN None
and CC None
a DT None
teaching JJ None
hospital NN None
. . None
Two CD None
hundred VBD None
and CC None
twenty-four JJ None
women NNS None
at IN None
12 CD None
to TO None
20 CD None
weeks NNS None
of IN None
gestation NN None
. . None
-DOCSTART- -X- N

heart NN Condition
failure NN Condition
outpatients NNS Condition
: : None
patients NNS None
under IN None
cardiologists NNS None
' POS None
care NN None
over IN None
long-term JJ None
follow-up NN None
One CD Condition
hundred VBD Condition
seventeen JJ Condition
patients NNS None
were VBD None
randomized VBN None
to TO None
usual JJ None
care NN None
, , None
and CC None
233 CD Condition
to TO None
additional JJ None
intervention NN None
. . None
patients NNS None
under IN None
the DT None
supervision NN None
of IN None
a DT None
cardiologist NN None
-DOCSTART- -X- N

16 CD Size
normal JJ None
adult NN Age
male NN Sex
volunteers NNS None
digoxin NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
mellitus RB Condition
. . None
patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
. . None
patients NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
with IN None
suboptimal JJ None
metabolic JJ None
control NN None
. . None
Patients NNS None
with IN None
a DT None
baseline NN None
haemoglobin NN None
A NNP None
( ( None
1c CD None
) ) None
( ( None
HbA NNP None
( ( None
1c CD None
) ) None
) ) None
of IN None
7.3 CD None
to TO None
11.0 CD None
% NN None
patients NNS None
with IN None
type JJ None
2 CD None
diabetes NNS None
-DOCSTART- -X- N

hyperglycemic JJ Condition
patients NNS Condition
with IN None
non-ST JJ None
elevation NN None
acute NN Condition
coronary JJ Condition
syndrome NN Condition
. . None
patients NNS None
with IN None
diabetes NNS None
receiving VBG None
standard JJ None
treatment NN None
for IN None
diabetes NNS None
and CC None
randomized VBN None
to TO None
ranolazine VB None
or CC None
placebo VB None
within IN None
the DT None
MERLIN-TIMI-36 NNP None
( ( None
MERLIN NNP None
) ) None
study NN None
. . None
patients NNS None
with IN None
diabetes NNS None
and CC None
A1C NNP None
of IN None
> NNP None
or=8-10 JJ None
% NN None
at IN None
randomization NN None
( ( None
n JJ None
= NNP None
171 CD None
) ) None
placebo-adjusted JJ None
( ( None
n JJ None
= NNP None
182 CD None
) ) None
patients NNS None
with IN None
FPG NNP None
of IN None
150-400 JJ None
mg/dl NN None
at IN None
randomization NN None
, , None
ranolazine NN None
( ( None
n JJ None
= NNP None
131 CD None
) ) None
placebo NN None
( ( None
n JJ None
= NNP None
147 CD None
) ) None
patients NNS None
with IN None
cardiovascular JJ None
disease NN None
and CC None
poorly RB None
controlled VBN None
diabetes NNS None
. . None
-DOCSTART- -X- N

during IN None
labor NN None
. . None
Eighty NNP None
healthy JJ None
women NNS None
beginning VBG None
active JJ None
labor NN None
( ( None
cervical JJ None
dilation NN None
4 CD None
cm NN None
) ) None
at IN None
term NN None
were VBD None
assigned VBN None
to TO None
receive VB None
fentanyl NN None
intravenously RB None
by IN None
either CC None
patient-controlled JJ None
administration NN None
( ( None
n=37 JJ None
) ) None
or CC None
nurse JJ None
administration NN None
on IN None
demand NN None
( ( None
n=43 JJ None
) ) None
-DOCSTART- -X- N

14 CD Size
outpatient JJ None
autistic JJ Condition
children NNS Age
. . None
Fourteen NNP Size
children NNS Age
( ( None
12 CD Size
infantile NN Condition
autism NN Condition
full JJ None
syndrome NN None
present NN None
, , None
2 CD Size
atypical JJ Condition
pervasive JJ Condition
developmental JJ Condition
disorder NN Condition
) ) None
between IN None
5 CD Age
and CC Age
13 CD Age
years NNS None
of IN None
age NN None
-DOCSTART- -X- N

individuals NNS None
with IN None
ASD NNP Condition
. . None
autism NN Condition
spectrum NN Condition
disorder NN Condition
( ( None
ASD NNP None
) ) None
people NNS None
with IN None
ASD NNP None
37 CD Size
participants NNS None
( ( None
22 CD Size
male NN Sex
, , None
15 CD Size
female NN Sex
) ) None
, , None
ages VBZ None
17-39 JJ Age
( ( None
M NNP None
= NNP None
31.49 CD Age
) ) None
years NNS None
at IN None
the DT None
beginning NN None
of IN None
the DT None
programme NN None
) ) None
diagnosed VBD None
with IN None
an DT None
ASD NNP None
and CC None
a DT None
group NN None
of IN None
34 CD Size
adults NNS None
with IN None
ASD NNP None
as IN None
control NN None
group NN None
( ( None
waiting VBG None
list NN None
) ) None
( ( None
19 CD Size
male NN Sex
, , None
15 CD Size
female NN Sex
) ) None
, , None
ages VBZ None
24-38 JJ Age
( ( None
M NNP None
= VBZ None
30 CD Age
at IN None
programme JJ None
initiation NN None
) ) None
years NNS None
. . None
individuals NNS None
with IN None
ASD NNP None
adults NNS Age
with IN None
ASD NNP None
. . None
-DOCSTART- -X- N

Twenty-two NNP Size
healthy JJ Condition
female NN Sex
volunteers NNS None
extra JJ None
1 CD None
group NN None
-DOCSTART- -X- N

continuous JJ Condition
ambulatory JJ Condition
peritoneal JJ Condition
dialysis NN Condition
( ( None
CAPD NNP Condition
) ) None
. . None
in IN None
six CD Size
patients NNS None
on IN None
continuous JJ Condition
ambulatory JJ Condition
peritoneal JJ Condition
dialysis NN Condition
ambulatory JJ Condition
peritoneal JJ Condition
dialysis NN Condition
. . None
-DOCSTART- -X- N

hypoxemia NN Condition
we PRP None
studied VBD None
20 CD Size
healthy JJ None
men NNS Sex
, , None
aged VBD None
20 CD Age
to TO Age
34 CD Age
years NNS None
, , None
using VBG None
a DT None
tight-fitting JJ None
face NN None
mask NN None
and CC None
an DT None
isocapnic JJ None
partial NN None
rebreathing NN None
system NN None
( ( None
a DT None
modified VBN None
anesthesia NN None
machine NN None
) ) None
-DOCSTART- -X- N

autism NN None
. . None
unfamiliar JJ None
child NN None
with IN None
autism NN None
. . None
Children NNP None
( ( None
N=296 NNP None
; : None
M NNP None
age=10.21 IN None
years NNS None
) ) None
unfamiliar JJ None
child NN None
with IN None
autism NN None
teacher NN None
hypothetical JJ None
mother NN None
hypothetical JJ None
father NN None
hypothetical JJ None
doctor NN None
. . None
Fifth-graders NNS None
-DOCSTART- -X- N

cancer-related JJ Condition
fatigue NN Condition
: : None
cancer-related JJ Condition
fatigue NN Condition
. . None
Eligible JJ None
adults NNS Age
with IN None
cancer NN Condition
Two CD Size
hundred VBD Size
ninety NN Size
patients NNS None
were VBD None
accrued VBN None
to TO None
this DT None
trial NN None
. . None
cancer-related JJ None
fatigue NN None
. . None
-DOCSTART- -X- N

horses NNS None
to TO None
be VB None
anaesthetised VBN Condition
with IN None
isoflurane NN None
. . None
Forty-eight JJ Size
horses NNS None
subjected VBN None
to TO None
elective VB Condition
surgery NN Condition
three CD Size
groups NNS None
of IN None
16 CD Size
horses NNS None
. . None
-DOCSTART- -X- N

cervical JJ Condition
vertigo NN Condition
] NN None
cervical JJ Condition
vertigo NN Condition
January NNP None
2002 CD None
to TO None
May NNP None
2008 CD None
, , None
168 CD Size
patients NNS None
with IN None
cervical JJ None
vertigo NNS None
were VBD None
randomly RB None
divided VBN None
into IN None
treatment NN None
group NN None
( ( None
84 CD Size
cases NNS None
) ) None
and CC None
the DT None
control NN None
group NN None
( ( None
84 CD Size
cases NNS None
) ) None
, , None
22 CD Size
males NNS Sex
and CC None
62 CD Size
females NNS Sex
in IN None
treatment NN None
group NN None
; : None
24 CD Size
males NNS Sex
and CC None
60 CD Size
females NNS Sex
in IN None
control NN None
group NN None
. . None
cervical JJ None
vertigo NN None
vertebral JJ Condition
body NN Condition
displacement NN Condition
-DOCSTART- -X- N

chronic JJ Condition
periodontitis NN Condition
. . None
patients NNS None
submitted VBN None
to TO None
different JJ None
treatments NNS None
of IN None
chronic JJ Condition
periodontitis NN Condition
and CC None
their PRP$ None
association NN None
with IN None
clinical JJ None
parameters NNS None
. . None
Sixty NNP Size
patients NNS None
were VBD None
assigned VBN None
-DOCSTART- -X- N

non-hyperlipidaemic JJ Condition
primary JJ Condition
hypertension NN Condition
. . None
hypercholesterolaemic JJ None
hypertensive JJ None
subjects NNS None
hypertensive JJ Condition
subjects NNS Condition
with IN Condition
lower JJR Condition
plasma NN Condition
cholesterol NN Condition
Fourteen JJ None
non-hyperlipidaemic JJ None
primary JJ None
hypertensive JJ None
subjects NNS None
( ( None
10 CD None
men NNS None
; : None
overall JJ None
mean?SD NN None
age NN None
58?12 CD None
years NNS None
) ) None
. . None
non-hyperlipidaemic JJ None
subjects NNS None
with IN None
primary JJ None
hypertension NN None
, , None
simvastatin JJ None
-DOCSTART- -X- N

after IN None
hip NN Condition
arthroplasty NN Condition
. . None
primary JJ Condition
total JJ Condition
hip NN Condition
arthroplasty NN Condition
186 CD Size
patients NNS None
received VBD None
either RB None
indomethacin JJ None
3 CD None
times NNS None
daily RB None
, , None
or CC None
rofecoxib VB None
twice RB None
, , None
and CC None
1 CD None
placebo NN None
, , None
daily RB None
for IN None
7 CD None
days NNS None
. . None
12 CD None
of IN None
the DT None
186 CD None
patients NNS None
included VBD None
discontinued VBN None
their PRP$ None
medication NN None
before IN None
the DT None
end NN None
of IN None
the DT None
trial NN None
due JJ None
to TO None
side VB None
effects NNS None
. . None
The DT None
remaining VBG None
174 CD Size
patients NNS None
were VBD None
included VBN None
in IN None
the DT None
analysis NN None
. . None
In IN None
the DT None
indomethacin NN None
group NN None
( ( None
n JJ None
= NNP None
89 CD Size
) ) None
, , None
77 CD None
patients NNS None
( ( None
87 CD None
% NN None
) ) None
showed VBD None
no DT None
HO NNP None
, , None
9 CD None
showed VBD None
HO NNP None
of IN None
grade NN None
1 CD None
and CC None
3 CD None
showed VBD None
HO NNP None
of IN None
grade NN None
2 CD None
according VBG None
to TO None
the DT None
Brooker NNP None
classification NN None
. . None
In IN None
the DT None
rofecoxib NN None
group NN None
( ( None
n JJ None
= NNP None
85 CD Size
) ) None
73 CD None
patients NNS None
( ( None
86 CD None
% NN None
) ) None
showed VBD None
no DT None
ossification NN None
, , None
9 CD None
showed VBD None
grade NN None
1 CD None
, , None
and CC None
3 CD None
showed VBD None
grade JJ None
2 CD None
. . None
-DOCSTART- -X- N

prospective JJ Condition
blood NN Condition
donors NNS Condition
: : None
Participants NNS None
were VBD None
randomly RB None
assigned VBN None
-DOCSTART- -X- N

non-variceal JJ Condition
upper JJ Condition
gastrointestinal JJ Condition
bleeding NN Condition
: : None
acute JJ Condition
non-variceal JJ Condition
gastrointestinal JJ Condition
bleeding NN Condition
. . None
A NNP None
total NN None
of IN None
48 CD Size
patients NNS None
with IN None
acute JJ Condition
upper JJ Condition
gastrointestinal NN Condition
bleeding NN Condition
due JJ None
to TO None
duodenal JJ Condition
or CC Condition
gastric JJ Condition
ulcer NN Condition
15 CD Size
patients NNS None
with IN None
Forrest NNP None
IB NNP None
30 CD Size
patients NNS None
with IN None
Forrest NNP None
II NNP None
. . None
-DOCSTART- -X- N

undernourished JJ Condition
older JJR Age
men NNS Sex
and CC Sex
women NNS Sex
. . None
In IN None
older JJR Age
people NNS Age
49 CD Size
community-dwelling NN None
, , None
undernourished JJ Condition
people NNS None
[ VBP None
Mini NNP Condition
Nutritional NNP Condition
Assessment NNP Condition
score VBD Condition
< JJ Condition
24 CD Condition
and CC None
low JJ Condition
body NN Condition
weight NN Condition
( ( None
body JJ Condition
mass NN Condition
index NN Condition
, , Condition
in IN Condition
kg/m NN Condition
( ( Condition
2 CD Condition
) ) Condition
: : Condition
< $ Condition
22 CD Condition
) ) None
or CC None
recent JJ Condition
weight JJ Condition
loss NN Condition
( ( None
> JJ None
7.5 CD None
% NN None
over IN None
3 CD None
mo NNS None
) ) None
] VBP None
aged VBN Age
> $ Age
65 CD Age
y NN None
( ( None
mean JJ None
age NN None
: : None
77 CD Age
y NN None
; : None
26 CD Size
women NNS Sex
and CC None
23 CD Size
men NNS Sex
) ) None
. . None
undernourished JJ Condition
older JJR Age
people NNS None
-DOCSTART- -X- N

men NNS Sex
treated VBN None
for IN None
symptomatic JJ Condition
benign NN Condition
prostatic JJ Condition
hyperplasia NN Condition
. . None
men NNS None
with IN None
lower JJR Condition
urinary JJ Condition
tract NN Condition
symptoms NNS Condition
associated VBN None
with IN None
benign JJ Condition
prostatic JJ Condition
hyperplasia NN Condition
( ( None
BPH NNP Condition
) ) None
. . None
men NNS None
aged VBN None
> NN Age
or CC Age
= $ Age
50 CD Age
years NNS None
372 CD Size
patients NNS None
355 CD Size
completing VBG None
the DT None
study NN None
. . None
At IN None
baseline NN None
, , None
64 CD None
% NN None
of IN None
the DT None
patients NNS None
reported VBD None
erectile JJ Condition
dysfunction NN Condition
( ( None
ED NNP Condition
) ) None
and CC None
63 CD None
% NN None
reported VBD None
ejaculatory JJ Condition
dysfunction NN Condition
( ( None
EjD NNP Condition
) ) None
. . None
-DOCSTART- -X- N

acute NN Condition
low JJ Condition
back RB Condition
pain NN Condition
with IN None
severe JJ None
disability NN None
: : None
patients NNS None
with IN None
low JJ Condition
back RB Condition
pain NN Condition
In IN None
Korea NNP None
Participants NNS None
with IN None
acute NN None
low JJ Condition
back RB Condition
pain NN Condition
and CC None
severe JJ None
functional JJ None
disability NN None
, , None
defined VBD None
as IN None
an DT None
Oswestry NNP None
Disability NNP None
Index NNP None
( ( None
ODI NNP None
) ) None
value NN None
> $ None
60 CD None
% NN None
-DOCSTART- -X- N

sweating NN None
threshold NN None
gain NN None
of IN None
sweating VBG None
. . None
Six NNP None
healthy JJ None
male NN None
volunteers NNS None
were VBD None
evaluated VBN None
-DOCSTART- -X- N

64 CD None
healthy JJ None
right-handed JJ None
human JJ None
subjects NNS None
covering VBG None
a DT None
wide JJ None
range NN None
of IN None
the DT None
adult NN None
lifespan NN None
( ( None
age NN None
range NN None
20-88 CD None
years NNS None
, , None
mean VB None
47.6 CD None
? . None
20.7 CD None
, , None
34 CD None
female NN None
) ) None
. . None
-DOCSTART- -X- N

femoropopliteal JJ Condition
arterial JJ Condition
disease NN Condition
266 CD Size
patients NNS None
with IN None
stenotic JJ Condition
or CC Condition
occluded VBN Condition
superficial JJ Condition
femoral JJ Condition
or CC Condition
popliteal JJ Condition
arteries NNS Condition
patients NNS None
undergoing VBG None
femoropopliteal JJ Condition
PTA NNP Condition
-DOCSTART- -X- N

chronic JJ Condition
hypotension NN Condition
. . None
50 CD Size
hypotensive JJ Condition
persons NNS None
-DOCSTART- -X- N

Menopausal NNP None
menopause-related JJ None
women NNS None
with IN None
vasomotor NN None
symptoms NNS None
. . None
Peri- NN None
and CC None
postmenopausal JJ None
women NNS None
, , None
40-62 JJ None
years NNS None
old JJ None
, , None
RESULTS NNP None
Among IN None
355 CD None
randomly NNS None
assigned VBN None
women NNS None
who WP None
average VBP None
age NN None
was VBD None
54.7 CD None
years NNS None
, , None
338 CD None
women NNS None
( ( None
95 CD None
% NN None
) ) None
completed VBD None
12-week JJ None
assessments NNS None
. . None
among IN None
healthy JJ None
sedentary JJ None
menopausal NN None
women NNS None
, , None
-DOCSTART- -X- N

cancer NN Condition
: : None
Patients NNPS None
with IN None
a DT None
resectable JJ Condition
esophageal NN Condition
cancer NN Condition
were VBD None
randomized VBN None
to TO None
OE NNP None
( ( None
n JJ None
= NNP None
13 CD Size
) ) None
or CC None
MIE NNP None
( ( None
n JJ None
= NNP None
14 CD Size
) ) None
. . None
All DT None
patients NNS None
received VBD None
neoadjuvant JJ None
chemoradiotherapy NN None
. . None
-DOCSTART- -X- N

Transurethral JJ Condition
prostate NN Condition
resection NN Condition
patients NNS None
with IN None
hematuria NNS Condition
of IN None
prostatic JJ None
origin NN None
. . None
patients NNS None
undergoing JJ None
transurethral JJ Condition
prostate NN Condition
resection NN Condition
A NNP None
total JJ None
70 CD Size
patients NNS None
scheduled VBN None
to TO None
undergo VB None
elective JJ Condition
transurethral JJ Condition
prostate NN Condition
resection NN Condition
were VBD None
randomized VBN None
68 CD Size
patients NNS None
who WP None
underwent JJ None
transurethral JJ Condition
prostate NN Condition
resection NN Condition
patients NNS None
undergoing JJ None
transurethral JJ Condition
prostate NN Condition
resection NN Condition
. . None
-DOCSTART- -X- N

postsurgical JJ Condition
gastroparesis NN Condition
syndrome NN Condition
] NNP None
postsurgical JJ None
gastroparesis NN None
syndrome NN None
( ( None
PGS NNP Condition
) ) None
. . None
Forty-one JJ Size
cases NNS None
of IN None
PGS NNP None
were VBD None
randomly RB None
divided VBN None
into IN None
3 CD None
groups NNS None
in IN None
order NN None
of IN None
visiting VBG None
. . None
( ( None
n JJ None
= NNP None
17 CD Size
) ) None
( ( None
n JJ None
= NNP None
12 CD Size
) ) None
( ( None
n JJ None
= NNP None
12 CD Size
) ) None
PGS NNP None
-DOCSTART- -X- N

postmenopausal JJ Condition
women NNS None
with IN None
and CC None
without IN None
hormone-replacement JJ Condition
therapy NN Condition
. . None
postmenopausal JJ Condition
women NNS None
consuming VBG None
a DT None
fish JJ None
oil NN None
supplement NN None
. . None
Forty-eight JJ Size
women NNS None
, , None
equally RB None
divided VBD None
between IN None
women NNS None
using VBG None
and CC None
not RB None
using VBG None
HRT NNP Condition
-DOCSTART- -X- N

glyceryltrinitrate NN None
induced VBN None
migraine NN Condition
. . None
Twelve CD Size
patients NNS None
with IN None
migraine NN Condition
without IN Condition
aura NN Condition
were VBD None
included VBN None
in IN None
a DT None
randomized JJ None
double JJ None
blind NN None
crossover NN None
study NN None
. . None
-DOCSTART- -X- N

Forty NNP Size
work-sites NNS None
-DOCSTART- -X- N

chronic JJ None
midportion NN None
Achilles NNP None
tendinopathy NN Condition
: : None
chronic JJ Condition
midportion NN Condition
Achilles NNP Condition
tendinopathy NN Condition
. . None
Sports NNP None
Medical NNP None
Department NNP None
, , None
The DT None
Hague NNP None
Medical NNP None
Centre NNP None
, , None
The DT None
Netherlands NNP None
. . None
Inclusion NNP None
criteria NNS None
were VBD None
: : None
age NN None
18-70 CD Age
years NNS Age
, , None
active JJ Condition
participation NN Condition
in IN Condition
sports NNS Condition
, , None
and CC None
tendon VB Condition
pain NN Condition
localised VBN Condition
at IN Condition
2-7 JJ Condition
cm NN Condition
from IN Condition
distal JJ Condition
insertion NN Condition
. . None
Exclusion NN None
criteria NNS None
were VBD None
: : None
insertional JJ None
disorders NNS None
, , None
partial JJ None
or CC None
complete JJ None
ruptures NNS None
, , None
or CC None
systemic JJ None
illness NN None
. . None
70 CD None
tendons NNS None
were VBD None
included VBN None
eccentric JJ None
group NN None
from IN None
50.1 CD None
to TO None
68.8 CD None
( ( None
p NN None
= RB None
0.001 CD None
) ) None
night NN None
splint NN None
group NN None
from IN None
49.4 CD None
to TO None
67.0 CD None
( ( None
p NN None
< RB None
0.001 CD None
) ) None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
high JJ Condition
normal JJ Condition
blood NN Condition
pressure NN Condition
and/or RB None
high JJ Condition
normal JJ Condition
blood NN Condition
glucose NN Condition
( ( Condition
SNAC NNP Condition
) ) Condition
: : None
individuals NNS None
with IN None
high JJ Condition
risk NN Condition
for IN Condition
disease NN Condition
patients NNS None
at IN None
risk NN None
( ( None
ie JJ None
high-normal JJ Condition
blood NN Condition
pressure NN Condition
or CC Condition
impaired JJ Condition
glucose JJ Condition
tolerance NN Condition
) ) None
. . None
Staged NNP None
Nutrition NNP None
and CC None
Activity NNP None
Counseling NNP None
( ( None
SNAC NNP None
) ) None
study NN None
cardiovascular JJ None
disease NN None
risk NN None
factors NNS None
and CC None
vascular JJ None
function NN None
in IN None
patients NNS None
at IN None
risk NN None
in IN None
primary JJ None
care NN None
. . None
-DOCSTART- -X- N

small JJ Condition
cell NN Condition
lung NN Condition
cancer NN Condition
Eighty-three JJ None
patients NNS None
with IN None
small JJ None
cell NN None
lung NN None
cancer NN None
74 CD None
patients NNS None
solid JJ None
cancer NN None
patients NNS None
-DOCSTART- -X- N

acute JJ Condition
heart NN Condition
failure NN Condition
: : None
Patients NNP None
Hospitalized NNP None
With IN None
Acute NNP Condition
Decompensated NNP Condition
Heart NNP Condition
Failure NNP Condition
and CC None
Volume NN Condition
Overload NNP Condition
Acute NNP Condition
heart NN Condition
failure NN Condition
2033 CD Size
patients NNS None
admitted VBN None
with IN None
acute JJ Condition
heart NN Condition
failure NN Condition
. . None
patients NNS None
with IN None
acute JJ Condition
heart NN Condition
failure NN Condition
-DOCSTART- -X- N

patients NNS None
with IN None
systolic JJ Condition
heart NN Condition
failure NN Condition
left JJ Condition
heart NN Condition
failure NN Condition
patients NNS None
with IN None
left JJ Condition
systolic JJ Condition
heart NN Condition
failure NN Condition
. . None
106 CD Size
patients NNS None
were VBD None
randomized VBN None
1:1 CD None
to TO None
sildenafil VB None
( ( None
n=53 NN Size
) ) None
or CC None
placebo NN None
( ( None
n=53 JJ Size
) ) None
. . None
Patients NNS None
received VBD None
sildenafil JJ None
25 CD None
mg NN None
twice RB None
a DT None
day NN None
or CC None
matching VBG None
placebo NN None
for IN None
the DT None
first JJ None
2 CD None
weeks NNS None
and CC None
50 CD None
mg NN None
3 CD None
times NNS None
a DT None
week NN None
for IN None
the DT None
remainder NN None
of IN None
the DT None
trial NN None
. . None
left JJ None
heart NN None
failure NN None
patients NNS None
-DOCSTART- -X- N

children NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
. . None
children NNS None
with IN None
autism NN None
spectrum NN None
disorders NNS None
( ( None
ASDs NNP None
) ) None
. . None
72 CD None
Danish JJ None
children NNS None
( ( None
aged VBN Age
4 CD Age
years NNS Age
to TO Age
10 CD Age
years NNS Age
11 CD Age
months NNS Age
) ) None
assigned VBD None
to TO None
diet VB None
( ( None
A DT None
) ) None
or CC None
non-diet JJ None
( ( None
B NNP None
) ) None
groups NNS None
by IN None
stratified JJ None
randomisation NN None
. . None
26 CD None
diet JJ None
children NNS None
and CC None
29 CD None
controls NNS None
children NNS None
diagnosed VBN None
with IN None
ASD NNP None
. . None
-DOCSTART- -X- N

acute JJ None
bronchiolitis NN None
One CD None
hundred CD None
and CC None
fifty-six JJ None
infants NNS None
aged VBN None
between IN None
7 CD None
weeks NNS None
and CC None
24 CD None
months NNS None
who WP None
had VBD None
had VBN None
an DT None
episode NN None
of IN None
wheezing NN None
and CC None
other JJ None
signs NNS None
and CC None
symptoms NNS None
of IN None
bronchiolitis NN None
-DOCSTART- -X- N

early JJ None
rheumatoid NN Condition
arthritis NN Condition
. . Condition
Fifty-seven JJ None
patients NNS None
younger JJR None
than IN None
65 CD None
years NNS None
with IN None
early JJ None
, , None
nonerosive JJ Condition
RA NNP Condition
7 CD Size
of IN Size
the DT Size
57 CD Size
patients NNS Size
( ( None
12.3 CD None
% NN None
) ) None
withdrew NN None
early JJ Condition
RA NNP Condition
. . None
-DOCSTART- -X- N

cesarean JJ None
section NN None
] NNP None
one CD None
hundred CD None
and CC None
eighty VB None
singleton NN None
primiparas IN None
undergoing VBG None
elective JJ None
cesarean JJ None
section NN None
, , None
in IN None
Qingdao NNP None
Municipal NNP None
Hospital NNP None
, , None
and CC None
Qingdao NNP None
Hiser NNP None
Medical NNP None
Center NNP None
, , None
from IN None
November NNP None
2011 CD None
to TO None
March NNP None
2012 CD None
, , None
were VBD None
randomly RB None
assigned VBN None
-DOCSTART- -X- N

Aged-care JJ Age
health NN None
services NNS None
in IN None
Sydney NNP None
, , None
Australia NNP None
. . None
131 CD Size
women NNS Sex
aged VBN None
75 CD Age
years NNS Age
or CC Age
older JJR Age
, , None
who WP None
had VBD None
two CD None
or CC None
more JJR None
falls NNS Condition
or CC None
one CD None
fall NN Condition
requiring VBG Condition
hospital JJ Condition
admission NN Condition
in IN None
the DT None
previous JJ None
year NN None
and CC None
who WP None
live VBP None
at IN None
home NN None
. . None
Sixty-one JJ Size
subjects NNS None
were VBD None
in IN None
the DT None
intervention NN None
group NN None
70 CD Size
in IN None
the DT None
control NN None
group NN None
. . None
participants NNS None
recruited VBD None
at IN None
home NN None
-DOCSTART- -X- N

patients NNS None
with IN None
ST-segment-elevation NNP Condition
myocardial JJ Condition
infarction NN Condition
. . None
patients NNS None
with IN None
acute JJ None
myocardial JJ None
infarction NN None
. . None
368 CD Size
patients NNS None
with IN None
first JJ None
ST-segment-elevation NNP None
myocardial JJ None
infarction NN None
undergoing VBG None
percutaneous JJ Condition
coronary JJ Condition
intervention NN Condition
( ( None
PCI NNP Condition
) ) None
. . None
patients NNS None
with IN None
ST-segment-elevation NNP None
myocardial JJ None
infarction NN None
. . None
-DOCSTART- -X- N

hemodialysis NN Condition
population NN None
. . None
Patients NNPS None
AVF NNP None
creation NN None
patients NNS None
Twenty-seven JJ Size
patients NNS None
participated VBN None
in IN None
the DT None
study NN None
. . None
patients NNS None
with IN None
BB NNP Condition
and CC None
PTFE NNP Condition
AVFs NNP Condition
. . None
-DOCSTART- -X- N

Two CD Size
hundred VBD Size
patients NNS None
with IN None
indications NNS None
for IN None
induction NN Condition
of IN Condition
labor NN Condition
and CC None
unfavorable JJ Condition
cervical JJ Condition
examinations NNS Condition
Of IN None
the DT None
200 CD Size
patients NNS None
enrolled VBD None
, , None
99 CD Size
were VBD None
randomized VBN None
to TO None
misoprostol VB None
and CC None
101 CD Size
to TO None
dinoprostone VB None
. . None
38 CD Size
patients NNS None
( ( None
19.3 CD None
% NN None
) ) None
had VBD None
cesarean JJ None
deliveries NNS None
. . None
-DOCSTART- -X- N

total JJ None
hip NN None
replacement NN None
. . None
total JJ None
hip NN None
replacement NN None
patients NNS None
in IN None
the DT None
bupivacaine NN None
only RB None
group NN None
bupivacaine-morphine JJ None
group NN None
-DOCSTART- -X- N

patients NNS None
with IN None
refractory JJ Condition
monosymptomatic JJ Condition
nocturnal JJ Condition
enuresis NN Condition
28 CD Size
patients NNS None
with IN None
refractory JJ None
monosymptomatic JJ None
nocturnal JJ None
enuresis NN None
patients NNS None
with IN None
refractory JJ None
monosymptomatic JJ None
nocturnal JJ None
enuresis NN None
-DOCSTART- -X- N

man NN Sex
. . None
man NN Sex
. . None
Eight NNP Size
normal JJ Condition
male NN Sex
volunteers NNS None
Metoclopramide NNP None
-DOCSTART- -X- N

patients NNS None
with IN None
in-stent JJ Condition
restenosis NN Condition
: : None
patients NNS None
with IN None
ISR NNP Condition
. . None
Three NNP Size
hundred VBD Size
symptomatic JJ Condition
patients NNS None
with IN None
ISR NNP Condition
-DOCSTART- -X- N

HIV-positive JJ Condition
homosexual JJ None
men NNS Sex
: : None
mildly RB None
symptomatic JJ None
HIV-positive JJ Condition
homosexual JJ Condition
and CC None
bisexual JJ Condition
men NNS Sex
. . None
Participants NNS None
were VBD None
recruited VBN None
largely RB None
during IN None
the DT None
era NN None
prior RB None
to TO None
highly RB None
active JJ None
antiretroviral JJ None
therapy NN None
( ( None
HAART NNP None
; : None
1992-1997 JJ None
) ) None
. . None
Men NNPS None
a DT None
psychoeducational JJ None
seminar NN None
group NN None
( ( None
n JJ None
= NNP None
46 CD Size
) ) None
. . None
Men NNP None
in IN None
the DT None
CBSM NNP None
group NN None
HIV-positive JJ None
homosexual JJ None
and CC None
bisexual JJ None
men NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
stable JJ Condition
schizophrenia NN Condition
: : None
patients NNS None
with IN None
stable JJ None
schizophrenia NN None
. . None
40 CD Size
patients NNS None
with IN None
schizophrenia NN Condition
( ( None
Diagnostic NNP None
and CC None
Statistical NNP None
Manual NNP None
of IN None
Mental NNP None
Disorders NNP None
, , None
Fourth NNP None
Edition NNP None
) ) None
who WP None
were VBD None
stabilized VBN None
on IN None
risperidone NN None
for IN None
a DT None
minimum NN None
of IN None
8 CD None
weeks NNS None
were VBD None
randomized VBN None
to TO None
either DT None
memantine NN None
( ( None
20 CD None
mg NN None
) ) None
or CC None
placebo NN None
in IN None
addition NN None
to TO None
risperidone VB None
, , None
6 CD None
mg/d NN None
, , None
for IN None
eight CD None
weeks NNS None
. . None
All DT None
40 CD None
patients NNS None
had VBD None
at IN None
least JJS None
one CD None
postbaseline NN None
measurement NN None
, , None
and CC None
38 CD Size
patients NNS None
completed VBD None
the DT None
trial NN None
. . None
-DOCSTART- -X- N

osteoarthritis NN Condition
of IN None
the DT None
ankle NN Condition
. . None
patients NNS None
with IN None
osteoarthritis NN None
( ( None
OA NNP Condition
) ) None
of IN None
the DT None
ankle NN None
. . None
43 CD None
ankles NNS None
( ( None
30 CD Size
patients NNS None
) ) None
with IN None
radiographic JJ None
Kellgren NNP None
Lawrence NNP None
grade VBD None
III NNP None
OA NNP None
-DOCSTART- -X- N

Endometrial JJ None
cytodiagnosis NN None
cytological JJ None
screening NN None
for IN None
endometrial JJ None
cancer NN None
315 CD Size
women NNS Size
( ( None
premenopause IN None
251 CD Size
, , None
postmenopause RB None
64 CD Size
) ) None
were VBD None
randomly RB None
assigned VBN None
to TO None
two CD None
groups NNS None
who WP None
underwent VBP None
the DT None
endometrial JJ None
cytological JJ None
screening NN None
with IN None
either CC None
the DT None
softcyte NN None
or CC None
the DT None
endocyte NN None
. . None
screening VBG None
for IN None
endometrial JJ None
cancer NN None
. . None
-DOCSTART- -X- N

full-thickness JJ Condition
rotator NN Condition
cuff NN Condition
tears NNS Condition
: : None
arthroscopic NN None
rotator NN None
cuff NN None
repair NN None
with IN None
and CC None
without IN None
acromioplasty JJ None
. . None
Eighty-six JJ Size
patients NNS None
sixty-eight NN Size
of IN None
them PRP None
completed VBD None
the DT None
study NN None
. . None
Four CD None
participants NNS None
( ( None
9 CD None
% NN None
) ) None
in IN None
the DT None
group NN None
that WDT None
had VBD None
arthroscopic VBN None
cuff JJ None
repair NN None
alone RB None
, , None
one CD None
with IN None
a DT None
Type-2 JJ None
and CC None
three CD None
with IN None
a DT None
Type-3 JJ None
acromion NN None
, , None
required VBN None
additional JJ None
surgery NN None
patients NNS None
who WP None
had VBD None
rotator NN None
cuff NN None
repair NN None
with IN None
or CC None
without IN None
acromioplasty JJ None
. . None
group NN None
-DOCSTART- -X- N

children NNS None
with IN None
autism NN None
. . None
children NNS None
with IN None
autism NN None
, , None
and CC None
2 CD None
) ) None
to TO None
assess VB None
the DT None
feasibility NN None
of IN None
home NN None
recordings NNS None
using VBG None
time-lapse JJ None
videosomnography NN None
in IN None
children NNS None
with IN None
autism NN None
. . None
Participants NNS None
were VBD None
a DT None
subset NN None
of IN None
subjects NNS None
from IN None
two CD None
double JJ None
blind NN None
, , None
placebo-control NN None
, , None
multi-center JJ None
clinical JJ None
trials NNS None
. . None
enrolled VBD None
some DT None
of IN None
the DT None
children NNS None
from IN None
each DT None
of IN None
the DT None
two CD None
trials NNS None
-DOCSTART- -X- N

low JJ None
birth NN None
weight NN None
infants NNS None
. . None
low JJ None
birth NN None
weight NN None
infants NNS None
. . None
low JJ None
birth NN None
weight NN None
infants NNS None
( ( None
average JJ None
birth NN None
weight NN None
1489 CD None
g NN None
) ) None
. . None
low JJ None
birth NN None
weight NN None
infants NNS None
-DOCSTART- -X- N

acute JJ Condition
ischaemic JJ Condition
stroke NN Condition
. . None
within IN None
the DT None
first JJ None
6 CD None
hours NNS None
of IN None
acute JJ Condition
ischaemic JJ Condition
stroke NN Condition
. . None
Patients NNS None
fulfilling VBG None
the DT None
selection NN None
criteria NNS None
Fourteen CD Size
patients NNS None
were VBD None
given VBN None
IVF NNP None
and CC None
13 CD Size
IAF NNP None
. . None
27 CD Size
patients NNS None
had VBD None
been VBN None
included VBN None
because IN None
of IN None
the DT None
mortality NN None
rate NN None
. . None
-DOCSTART- -X- N

participants NNS Condition
with IN Condition
knee NN Condition
osteoarthritis NN Condition
: : Condition
participants NNS Condition
with IN Condition
knee NN Condition
osteoarthritis NN Condition
. . Condition
Participants NNS None
( ( None
N=106 NNP None
) ) None
-DOCSTART- -X- N

benign JJ None
prostatic JJ None
hyperplasia NN None
: : None
patients NNS None
with IN None
benign JJ None
prostatic JJ None
hyperplasia NN None
618 CD None
patients NNS None
, , None
418 CD None
( ( None
68 CD None
% NN None
) ) None
target NN None
BPH NNP None
population NN None
-DOCSTART- -X- N

prostate NN Condition
cancer NN Condition
men NNS Sex
's POS Sex
( ( None
45-70 CD Age
years NNS None
) ) None
Internet NNP None
access NN None
and CC None
their PRP$ None
willingness NN None
to TO None
use VB None
a DT None
web- JJ None
vs. FW None
a DT None
print-based JJ None
tool NN None
. . None
men NNS None
's POS None
informed VBN None
decision NN None
making VBG None
-DOCSTART- -X- N

paediatric JJ Age
cuffed NN Condition
tracheal NN Condition
tubes NNS Condition
50 CD Size
children NNS Age
undergoing VBG None
general JJ Condition
anaesthesia NN Condition
with IN Condition
tracheal JJ Condition
intubation NN Condition
and CC None
standardized JJ Condition
anaesthesia NN Condition
technique NN Condition
( ( None
including VBG None
66 CD None
% NN None
N2O NNP None
in IN None
O2 NNP None
) ) None
and CC None
ventilator JJ Condition
settings NNS Condition
. . None
-DOCSTART- -X- N

90 CD Size
medical JJ Condition
students NNS None
without IN None
previous JJ None
experience NN None
in IN None
laparoscopic NN None
techniques NNS None
were VBD None
randomly RB None
assigned VBN None
to TO None
undergo VB None
one CD None
of IN None
three CD None
procedures NNS None
: : None
CLS NNP None
, , None
SPLS NNP None
using VBG None
two CD None
pre-bent JJ None
instruments NNS None
( ( None
SPLS-pp NNP None
) ) None
, , None
or CC None
SPLS NNP None
using VBG None
one CD None
pre-bent NN None
and CC None
one CD None
straight NN None
laparoscopic NN None
instrument NN None
( ( None
SPLS-ps NNP None
) ) None
. . None
-DOCSTART- -X- N

pelvic JJ Condition
inflammatory JJ Condition
disease NN Condition
( ( None
PID NNP Condition
) ) None
. . None
43 CD Size
participants NNS None
, , None
40 CD Size
were VBD None
randomized VBN None
to TO None
tissue VB None
sampling VBG None
. . None
PID NNP None
. . None
-DOCSTART- -X- N

following VBG None
sudden JJ None
cardiac JJ Condition
arrest NN Condition
: : None
sudden JJ None
cardiac JJ None
arrest NN None
survivors NNS None
. . None
Survivors NNPS None
of IN None
out-of-hospital JJ None
ventricular JJ None
fibrillation NN None
or CC None
asystole NN None
( ( None
N NNP None
= NNP None
129 CD Size
) ) None
, , None
documented VBN None
by IN None
electrocardiograms NNS None
from IN None
registries NNS None
of IN None
a DT None
citywide NN None
Medic NNP None
One NNP None
unit NN None
and CC None
two CD None
countywide NN None
emergency NN None
units NNS None
sudden JJ None
cardiac JJ None
arrest NN None
survivors NNS None
. . None
-DOCSTART- -X- N

three-centre JJ Condition
study NN Condition
investigated VBD Condition
the DT Condition
preference NN Condition
of IN Condition
cystic JJ Condition
fibrosis NN Condition
( ( Condition
CF NNP Condition
) ) Condition
patients NNS Condition
Fifty-nine JJ None
patients NNS None
with IN None
a DT None
mean JJ None
age NN None
10 CD None
years NNS None
( ( None
range VB None
3-17 NNP None
) ) None
51 CD None
of IN None
54 CD None
patients NNS None
who WP None
completed VBD None
the DT None
study NN None
CF NNP None
children NNS None
-DOCSTART- -X- N

type NN None
1 CD None
diabetes NNS None
: : None
multicenter NN None
436 CD None
children NNS None
and CC None
adults NNS None
with IN None
type JJ None
1 CD None
diabetes NNS None
-DOCSTART- -X- N

adolescents NNS Condition
with IN Condition
higher JJR Condition
blood NN Condition
pressure NN Condition
] NNP Condition
adolescents NNS None
with IN None
higher JJR None
blood NN None
pressure NN None
. . None
220 CD None
adolescents NNS None
with IN None
higher JJR None
blood NN None
pressure NN None
, , None
aged VBD None
18 CD None
- : None
22 CD None
years NNS None
, , None
who WP None
were VBD None
randomly RB None
divided VBN None
into IN None
supplementary JJ None
group NN None
( ( None
n JJ None
= NNP None
110 CD None
) ) None
and CC None
control NN None
group NN None
( ( None
n JJ None
= NNP None
110 CD None
) ) None
. . None
Each DT None
of IN None
the DT None
subjects NNS None
in IN None
the DT None
supplementary JJ None
group NN None
and CC None
their PRP$ None
family NN None
members NNS None
adolescents NNS None
with IN None
higher JJR None
blood NN None
pressure NN None
. . None
-DOCSTART- -X- N

primary JJ None
stenting NN None
of IN None
totally RB None
occluded JJ None
native JJ None
coronary JJ None
arteries NNS None
: : None
total JJ Condition
coronary JJ Condition
occlusions NNS Condition
patients NNS None
enrolled VBN None
in IN None
the DT None
Primary NNP None
Stenting NNP None
of IN None
Totally NNP None
Occluded NNP None
Native NNP None
Coronary NNP None
Arteries NNP None
II NNP None
study NN None
. . None
Patients NNPS None
with IN None
totally RB Condition
occluded JJ Condition
coronary JJ Condition
arteries NNS Condition
( ( None
100 CD Size
patients NNS None
) ) None
bare-metal JJ None
BxVelocity NNP None
stents NNS None
( ( None
BMSs NNP None
) ) None
( ( None
Cordis NNP None
) ) None
( ( None
100 CD Size
patients NNS None
) ) None
-DOCSTART- -X- N

working VBG Condition
population NN Condition
volunteers NNS None
from IN None
1100 CD Size
eligible JJ None
employees NNS None
of IN None
a DT None
Finnish JJ None
insurance NN None
company NN None
. . None
-DOCSTART- -X- N

procedure NN Condition
for IN Condition
prolapse NN Condition
and CC Condition
hemorrhoids NNS Condition
] NNP None
From IN None
November NNP None
2002 CD None
to TO None
July NNP None
2003 CD None
, , None
80 CD Size
patients NNS None
who WP None
received VBD None
PPH NNP None
-DOCSTART- -X- N

superficial JJ None
bladder NN None
cancer NN None
superficial JJ None
bladder NN None
cancer NN None
. . None
total NN None
of IN None
99 CD None
subjects NNS None
with IN None
resected JJ None
superficial JJ None
bladder NN None
cancer NN None
( ( None
pTa NN None
, , None
pT1 NN None
) ) None
bladder NN None
cancer NN None
. . None
-DOCSTART- -X- N

outpatients NNS None
with IN None
cardiovascular JJ Condition
disease NN Condition
or CC None
cardiovascular JJ Condition
risk NN Condition
: : None
patients NNS None
with IN None
cardiovascular JJ Condition
disease NN Condition
( ( None
CVD NNP Condition
) ) None
patients NNS None
with IN None
CVD NNP Condition
. . None
patients NNS None
with IN None
CVD NNP None
and/or VBP None
high JJ Condition
or CC Condition
intermediate JJ Condition
cardiovascular NN Condition
( ( Condition
CV NNP Condition
) ) Condition
risk NN Condition
attending VBG None
community NN None
pharmacies NNS None
in IN None
Spain NNP None
. . None
Patients NNPS None
aged VBD None
25 CD Age
to TO Age
74 CD Age
years NNS None
attending VBG None
community NN None
pharmacies NNS None
with IN None
a DT None
prescription NN None
for IN None
at IN None
least JJS None
1 CD None
drug NN None
indicated VBN None
for IN None
CVD NNP None
or CC None
CV NNP Condition
risk NN None
factors NNS None
Patients NNS None
were VBD None
recruited VBN None
from IN None
December NNP None
2005 CD None
to TO None
September NNP None
2006 CD None
714 CD Size
patients NNS None
mean JJ None
[ NNP None
SD NNP None
] NNP None
age NN None
was VBD None
62.8 CD Age
[ JJ None
8.1 CD None
] JJ None
years NNS None
. . None
patients NNS None
with IN None
CVD NNP None
and/or VBP None
high JJ None
or CC None
intermediate JJ None
CV NNP None
risk NN None
attending VBG None
community NN None
pharmacies NNS None
in IN None
Spain NNP None
. . None
-DOCSTART- -X- N

Four CD Size
healthy JJ Condition
volunteers NNS None
with IN None
significant JJ None
erythema NN Condition
and CC None
telangiectasia NN Condition
on IN Condition
the DT Condition
face NN Condition
telangiectasias NN None
. . None
-DOCSTART- -X- N

individuals NNS None
with IN None
serious JJ Condition
mental JJ Condition
illness NN Condition
( ( None
SMI NNP Condition
) ) None
receiving VBG None
antipsychotic JJ None
drug NN None
therapy NN None
. . None
individuals NNS None
with IN None
SMI NNP None
over IN None
8 CD None
weeks NNS None
. . None
30 CD None
individuals NNS None
( ( None
BMI NNP None
? . None
28 CD None
kg/m NN None
( ( None
2 CD None
) ) None
) ) None
were VBD None
for IN None
individuals NNS None
with IN None
SMI NNP None
and CC None
patients NNS None
taking VBG None
antipsychotic JJ None
medications NNS None
; : None
financial JJ None
-DOCSTART- -X- N

home-visit JJ None
invitation NN None
increase NN None
Pap NNP None
smear JJ None
screening NN None
in IN None
Samliem NNP None
, , None
Khon NNP None
Kaen NNP None
, , None
Thailand NNP None
cervical JJ Condition
cancer NN Condition
screening VBG Condition
in IN None
women NNS Sex
between IN None
35 CD Age
and CC Age
60 CD Age
years NNS None
of IN None
age NN None
. . None
randomly RB None
recruited VBD None
304 CD Size
women NNS None
from IN None
the DT None
Samliem NNP None
inner-city NN None
community NN None
, , None
Khon NNP None
Kaen NNP None
, , None
Northeast NNP None
Thailand NNP None
, , None
and CC None
assigned VBD None
participants NNS None
58 CD None
of IN None
158 CD Size
women NNS None
in IN None
the DT None
intervention NN None
zone NN None
and CC None
46 CD None
of IN None
146 CD Size
in IN None
the DT None
control NN None
zone NN None
were VBD None
excluded VBN None
from IN None
the DT None
study NN None
because IN None
of IN None
having VBG None
had VBD None
a DT None
Pap NNP None
smear NN None
within IN None
5 CD None
years NNS None
, , None
but CC None
these DT None
were VBD None
included VBN None
in IN None
the DT None
final JJ None
analysis NN None
. . None
100 CD None
women NNS None
in IN None
the DT None
intervention NN None
group NN None
100 CD None
women NNS None
in IN None
the DT None
control NN None
group NN None
-DOCSTART- -X- N

bronchial JJ None
provocation NN None
with IN None
methacholine JJ None
] NN None
A DT None
bronchial JJ None
provocation NN None
challenge NN None
test NN None
was VBD None
conducted VBN None
with IN None
30 CD Size
subjects NNS Condition
using VBG None
metacholin NN None
. . None
-DOCSTART- -X- N

postoperative JJ None
disease NN None
management NN None
of IN None
moderate JJ Condition
to TO Condition
severe JJ Condition
endometriosis NN Condition
. . None
patients NNS None
treated VBN None
with IN None
triptorelin NN None
every DT None
6 CD None
weeks NNS None
. . None
Kwong NNP None
Wah NNP None
Hospital NNP None
, , None
a DT None
large JJ None
public JJ None
hospital NN None
in IN None
an DT None
urban JJ None
location NN None
( ( None
Hong NNP None
Kong NNP None
) ) None
. . None
Forty NNP Size
patients NNS None
after IN None
their PRP$ None
first JJ None
conservative JJ None
operation NN None
for IN None
endometriosis NN None
, , None
with IN None
surgical JJ None
confirmation NN None
of IN None
revised VBN None
AFS NNP Condition
stage NN Condition
III NNP Condition
or CC Condition
IV NNP Condition
endometriosis NN Condition
. . None
-DOCSTART- -X- N

coronary JJ None
artery NN None
surgery NN None
. . None
coronary JJ Condition
artery JJ Condition
bypass NN Condition
grafting NN Condition
45 CD Size
hypertensive JJ Condition
coronary JJ Condition
bypass NN Condition
patients NNS None
-DOCSTART- -X- N

21 CD Size
healthy JJ Condition
subjects NNS Condition
with IN None
different JJ None
fitness NN Condition
levels NNS Condition
. . None
-DOCSTART- -X- N

outpatients NNS None
with IN None
a DT None
major JJ None
depressive JJ Condition
disorder NN Condition
outpatients NNS None
with IN None
primary JJ Condition
depression NN Condition
-DOCSTART- -X- N

for IN None
advanced JJ None
myeloid NN None
leukemia NN None
and CC None
MDS NNP None
. . None
in IN None
patients NNS None
with IN None
myeloid JJ None
leukemia NN None
undergoing VBG None
allogeneic JJ None
stem NN None
cell NN None
transplantation NN None
( ( None
allo-SCT JJ None
) ) None
. . None
. . None
Fifty-one CD None
patients NNS None
have VBP None
been VBN None
enrolled VBN None
with IN None
days NNS None
. . None
There EX None
were VBD None
32 CD None
males NNS None
and CC None
19 CD None
females NNS None
, , None
with IN None
a DT None
median JJ None
age NN None
of IN None
45 CD None
years NNS None
( ( None
range NN None
: : None
6-59 JJ None
) ) None
. . None
Nine JJ None
patients NNS None
had VBD None
chronic JJ None
myeloid NN None
leukemia NN None
( ( None
CML NNP None
) ) None
( ( None
BC NNP None
: : None
2 CD None
, , None
second JJ None
AP NNP None
: : None
3 CD None
, , None
and CC None
tyrosine-kinase JJ None
inhibitor NN None
refractory NN None
first RB None
chronic JJ None
phase NN None
[ NNP None
CP NNP None
] NN None
: : None
4 CD None
) ) None
. . None
Forty-two JJ None
patients NNS None
had VBD None
AML NNP None
: : None
14 CD None
were VBD None
induction NN None
failures NNS None
, , None
8 CD None
in IN None
first JJ None
chemotherapy-refractory JJ None
relapse NN None
, , None
7 CD None
in IN None
untreated JJ None
relapse NN None
, , None
3 CD None
in IN None
second JJ None
or CC None
subsequent JJ None
relapse NN None
, , None
4 CD None
were VBD None
in IN None
second JJ None
complete JJ None
remission NN None
( ( None
CR NNP None
) ) None
, , None
and CC None
3 CD None
in IN None
second JJ None
CR NNP None
without IN None
platelet NN None
recovery NN None
( ( None
CRp NNP None
) ) None
, , None
2 CD None
were VBD None
in IN None
high-risk JJ None
CR1 NNP None
. . None
Finally NNP None
, , None
1 CD None
patient NN None
was VBD None
in IN None
first JJ None
CRp NNP None
. . None
Graft-versus-host NNP None
engrafted VBN None
. . None
Forty-one CD None
patients NNS None
had VBD None
active JJ None
leukemia NN None
at IN None
the DT None
time NN None
of IN None
transplant NN None
, , None
and CC None
35 CD None
achieved VBN None
CR NNP None
( ( None
. . None
Twenty CD None
in IN None
high-risk JJ None
myeloid JJ None
leukemia NN None
patients NNS None
; : None
( ( None
2 CD None
) ) None
clofarabine NN None
-DOCSTART- -X- N

male JJ None
patients NNS None
. . None
in IN None
male JJ None
patients NNS None
with IN None
urethral JJ None
strictures NNS None
Fifty NNP None
patients NNS None
aged VBD None
22 CD None
to TO None
83 CD None
( ( None
mean JJ None
age NN None
61.8 CD None
) ) None
with IN None
primary JJ None
( ( None
n JJ None
= NN None
26 CD None
, , None
52 CD None
% NN None
) ) None
and CC None
recurrent NN None
( ( None
n JJ None
= NN None
24 CD None
, , None
48 CD None
% NN None
) ) None
urethral JJ None
strictures VBZ None
0.3 CD None
to TO None
2.4 CD None
cm NNS None
long RB None
qualified VBD None
for IN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

cardiovascular JJ Condition
events NNS Condition
and CC None
cancer NN Condition
: : None
cancer NN Condition
and CC None
cardiovascular JJ Condition
events NNS Condition
. . None
cancer NN None
, , None
cancer NN None
death NN None
, , None
and CC None
major JJ None
cardiovascular JJ None
events NNS None
. . None
international JJ None
patients NNS None
at IN None
least JJS None
55 CD Age
years NNS None
old JJ None
with IN None
vascular JJ Condition
disease NN Condition
or CC None
diabetes VBZ Condition
mellitus NN Condition
was VBD None
extended VBN None
( ( None
HOPE-The NNP None
Ongoing NNP None
Outcomes NNP None
[ NNP None
HOPE-TOO NNP None
] NNP None
) ) None
between IN None
April NNP None
16 CD None
, , None
1999 CD None
, , None
and CC None
May NNP None
26 CD None
, , None
2003 CD None
. . None
267 CD None
HOPE NNP None
centers NNS None
that WDT None
had VBD None
enrolled VBN None
9541 CD Size
patients NNS None
, , None
174 CD None
centers NNS None
participated VBN None
in IN None
the DT None
HOPE-TOO NNP None
trial NN None
. . None
7030 CD Size
patients NNS None
enrolled VBN None
at IN None
these DT None
centers NNS None
, , None
916 CD None
were VBD None
deceased VBN None
at IN None
the DT None
beginning NN None
of IN None
the DT None
extension NN None
, , None
1382 CD None
refused VBD None
participation NN None
, , None
3994 CD None
continued VBD None
to TO None
take VB None
the DT None
study NN None
intervention NN None
, , None
and CC None
738 CD None
agreed VBD None
to TO None
passive VB None
follow-up NN None
. . None
patients NNS None
with IN None
vascular JJ None
disease NN None
or CC None
diabetes VBZ None
mellitus NNS None
-DOCSTART- -X- N

small JJ None
cell NN None
lung NN None
cancer NN None
patients NNS None
. . None
small JJ None
cell NN None
lung NN None
cancer NN None
( ( None
SCLC NNP None
) ) None
patients NNS None
11 CD None
patients NNS None
received VBD None
either RB None
standard JJ None
( ( None
four CD None
weekly RB None
) ) None
chemotherapy NN None
with IN None
ifosfamide NN None
, , None
carboplatin NN None
, , None
and CC None
etoposide RB None
( ( None
ICE NNP None
) ) None
or CC None
accelerated VBN None
( ( None
two CD None
weekly RB None
) ) None
ICE NNP None
with IN None
filgrastim NN None
( ( None
granulocyte JJ None
-DOCSTART- -X- N

vaginal JJ Condition
candidosis NN Condition
: : None
vaginal JJ Condition
candidosis NN Condition
. . None
treatment NN None
of IN None
vaginal JJ Condition
candidosis NN Condition
in IN None
a DT None
randomized JJ None
study NN None
in IN None
Finland NNP None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
transient JJ Condition
ischaemic JJ Condition
attacks NNS Condition
. . None
25 CD Size
male JJ Sex
patients NNS None
with IN None
transient JJ Condition
ischaemic JJ Condition
attacks NNS Condition
( ( None
TIA NNP Condition
) ) None
. . None
In IN None
addition NN None
, , None
the DT None
same JJ None
parameters NNS None
were VBD None
studied VBN None
in IN None
a DT None
group NN None
of IN None
20 CD Size
healthy JJ Condition
males NNS Sex
of IN None
matched JJ None
age NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
metastatic JJ Condition
renal NN Condition
cell NN Condition
carcinoma VBZ Condition
previously RB None
treated VBN None
with IN None
a DT None
tyrosine JJ None
kinase NN None
inhibitor NN None
and CC None
everolimus VB None
36 CD Size
patients NNS None
treated VBN None
in IN None
France NNP None
in IN None
the DT None
RECORD-1 JJ None
Trial NNP None
. . None
patients NNS None
with IN None
metastatic JJ None
renal NN None
cell NN None
carcinoma NN None
( ( None
mRCC NN Condition
) ) None
patients NNS None
with IN None
disease JJ None
progression NN None
after IN None
a DT None
TKI-everolimus JJ None
sequence NN None
. . None
patients NNS None
enrolled VBN None
in IN None
RECORD-1 NNP None
( ( None
Renal NNP Condition
Cell NNP Condition
Cancer NNP Condition
Treatment NNP None
With IN None
Oral NNP None
RAD001 NNP None
Given NNP None
Daily NNP None
) ) None
at IN None
French JJ None
sites NNS None
. . None
patients NNS None
treated VBN None
with IN None
a DT None
TKI-everolimus-TKI JJ None
sequence NN None
. . None
Thirty-six JJ None
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
rheumatoid JJ Condition
arthritis NN Condition
and CC None
an DT None
inadequate JJ None
response NN None
to TO None
1 CD None
or CC None
more JJR None
tumor JJ None
necrosis NN None
factor NN None
inhibitors NNS None
: : None
patients NNS None
with IN None
rheumatoid JJ None
arthritis NN None
( ( None
RA NNP Condition
) ) None
who WP None
had VBD None
an DT None
inadequate JJ None
response NN None
to TO None
tumor VB None
necrosis NN None
factor NN None
( ( None
TNF NNP None
) ) None
inhibitors NNS None
. . None
Patients NNPS None
in IN None
REFLEX NNP None
PBO-randomized JJ None
patients NNS None
480 CD None
patients NNS None
received VBN None
? . None
1 CD None
RTX NNP None
course NN None
. . None
-DOCSTART- -X- N

during IN None
opioid JJ Condition
maintenance NN Condition
treatment NN Condition
. . None
drug NN Condition
users NNS Condition
128 CD Size
opioid JJ Condition
maintenance NN Condition
patients NNS Condition
receiving VBG None
either CC None
methadone NN None
or CC None
LAAM NNP None
. . None
high JJ None
rates NNS None
of IN None
cocaine NN Condition
use NN Condition
disorders NNS Condition
-DOCSTART- -X- N

after IN None
major JJ Condition
abdominal JJ Condition
surgery NN Condition
. . None
Forty NNP Size
patients NNS None
first JJ None
18 CD None
hours NNS None
after IN None
major JJ Condition
abdominal JJ Condition
surgery NN Condition
. . None
-DOCSTART- -X- N

adolescent JJ Age
and CC None
young JJ Age
adult NN Age
children NNS Age
of IN None
opiate JJ Condition
addicts NNS Condition
: : None
adolescent NN Age
and CC None
young JJ Age
adult NN Age
children NNS Age
of IN None
parents NNS None
enrolled VBN None
in IN None
methadone NN None
treatment NN None
for IN None
opiate JJ Condition
addiction NN Condition
. . None
Data NNS None
are VBP None
from IN None
151 CD Size
participants NNS None
( ( None
80 CD Size
males NNS Sex
, , None
71 CD Size
females NNS Sex
) ) None
in IN None
the DT None
Focus NNP None
on IN None
Families NNP None
( ( None
FOF NNP None
) ) None
project NN None
, , None
a DT None
randomized JJ None
trial NN None
of IN None
a DT None
family NN None
intervention NN None
and CC None
a DT None
study NN None
of IN None
the DT None
development NN None
of IN None
at-risk JJ None
children NNS None
. . None
The DT None
study NN None
participants NNS None
are VBP None
children NNS None
of IN None
parents NNS None
enrolled VBN None
in IN None
methadone NN None
treatment NN None
between IN None
1990 CD None
and CC None
1993 CD None
. . None
Participants NNS None
were VBD None
interviewed VBN None
in IN None
2005 CD None
when WRB None
they PRP None
ranged VBD None
in IN None
age NN None
from IN None
15 CD Age
to TO Age
29 CD Age
years NNS None
. . None
-DOCSTART- -X- N

patients NNS Condition
with IN Condition
myasthenia JJ Condition
gravis NN Condition
. . Condition
Patients NNPS None
with IN None
myasthenia NNP None
gravis FW None
receive JJ None
pyridostigmine NN None
, , None
an DT None
anticholinesterase NN None
agent NN None
patients NNS None
with IN None
myasthenia JJ None
gravis NN None
on IN None
pyridostigmine NN None
therapy NN None
. . None
Medically NNP None
( ( None
oral JJ None
pyridostigmine NN None
) ) None
well-controlled JJ None
adult NN None
patients NNS None
with IN None
myasthenia JJ None
gravis NNS None
who WP None
were VBD None
posted VBN None
for IN None
thymectomy NN None
Fourteen JJ None
patients NNS None
myasthenia JJ None
gravis NN None
-DOCSTART- -X- N

young JJ Age
children NNS Age
with IN None
autism NN Condition
. . None
Children NNP None
with IN None
autism NN None
three CD Size
young JJ None
children NNS None
with IN None
autism NN None
and CC None
their PRP$ None
mothers NNS None
. . None
young JJ None
children NNS None
with IN None
autism NN None
parents NNS None
. . None
-DOCSTART- -X- N

hypercholesterolemia NN Condition
. . None
Two CD Size
hundred VBD Size
one CD Size
male NN Sex
and CC Sex
female JJ Sex
subjects NNS None
, , None
aged VBD None
20 CD Age
to TO Age
70 CD Age
years NNS None
, , None
with IN None
elevated VBN Condition
low-density NN Condition
lipoprotein NN Condition
cholesterol NN None
values NNS None
( ( None
in IN None
the DT None
75th CD Condition
to TO Condition
95th CD Condition
percentiles NNS Condition
) ) None
, , None
participated VBN None
-DOCSTART- -X- N

HER2-positive JJ Condition
breast NN Condition
cancer NN Condition
: : Condition
patients NNS None
who WP None
will MD None
benefit VB None
from IN None
targeted JJ None
anticancer NN None
therapies NNS None
. . None
455 CD None
women NNS None
with IN None
invasive JJ None
human JJ None
epidermal JJ None
growth NN None
factor NN None
receptor NN None
2 CD None
( ( None
HER2 NNP None
) ) None
-positive VBP None
breast NN None
cancer NN None
assessed VBN None
in IN None
a DT None
subset NN None
of IN None
patients NNS None
. . None
Eighty-six JJ Size
patients NNS Size
underwent JJ Size
( ( Size
18 CD Size
) ) Size
F-FDG CD Size
PET/CT NNP Size
-DOCSTART- -X- N

patients NNS None
with IN None
peptic JJ Condition
ulcer NN Condition
bleeding NN Condition
: : None
Twelve NNP Size
Helicobacter NNP Condition
pylori NN Condition
( ( Condition
+ NNP Condition
) ) Condition
patients NNS Condition
and CC None
12 CD Size
H. NNP Condition
pylori NN Condition
( ( Condition
- : Condition
) ) Condition
subjects NNS None
were VBD None
included VBN None
. . None
peptic JJ Condition
ulcer NN Condition
bleeding NN Condition
-DOCSTART- -X- N

children NNS Age
with IN None
autistic JJ Condition
disorder NN Condition
: : None
children NNS Age
with IN None
autistic JJ Condition
disorder NN Condition
; : None
children NNS Age
with IN None
autistic JJ Condition
disorder NN Condition
parallel JJ None
groups NNS None
design NN None
, , None
12 CD Size
children NNS Age
with IN None
DSM-IV NNP Condition
autistic JJ Condition
disorder NN Condition
( ( None
mean JJ None
age NN None
7.8+/-2.1 CD Age
years NNS None
) ) None
were VBD None
randomized VBN None
children NNS Age
with IN None
autistic JJ Condition
disorder NN Condition
. . None
-DOCSTART- -X- N

nodular JJ Condition
basal NN Condition
cell NN Condition
carcinoma NN Condition
. . None
nodular JJ Condition
basal NN Condition
cell NN Condition
carcinoma NN Condition
( ( None
BCC NNP Condition
) ) None
. . None
patients NNS None
with IN None
nodular JJ Condition
BCC NNP Condition
. . None
Twenty NNP Size
patients NNS None
Twenty NNP Size
patients NNS None
imiquimod NN None
( ( None
n JJ None
= NNP None
10 CD Size
) ) None
vehicle NN None
( ( None
n JJ None
= NNP None
10 CD Size
) ) None
-DOCSTART- -X- N

686 CD Size
patients NNS None
with IN None
stable JJ Condition
angina NNS Condition
myocardial JJ Condition
infarction NN Condition
accompanied VBN None
by IN None
serum NN None
enzyme NN None
elevations NNS None
with IN None
or CC None
without IN None
electrocardiographic JJ None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
. . None
Twenty NNP Size
children NNS Age
with IN None
autism NN Condition
( ( None
mean JJ None
age NN None
, , None
5 CD Age
years NNS Age
) ) None
were VBD None
recruited VBN None
for IN None
the DT None
study NN None
from IN None
a DT None
school NN None
for IN None
children NNS Age
with IN None
autism NN Condition
. . None
imitation NN None
( ( None
n JJ None
= NNP None
10 CD Size
) ) None
or CC None
contingently RB None
responsive JJ None
( ( None
n JJ None
= NNP None
10 CD Size
) ) None
-DOCSTART- -X- N

patients NNS None
with IN None
hepatitis NN Condition
B NNP Condition
e VBZ Condition
antigen-negative JJ Condition
chronic JJ Condition
hepatitis NN Condition
B NNP Condition
. . None
chronic JJ Condition
hepatitis NN Condition
B NNP Condition
( ( None
CHB NNP Condition
) ) None
. . None
Thirteen NNP Size
patients NNS None
with IN None
HBeAg-negative JJ None
CHB NNP None
HBeAg-negative JJ Condition
CHB NNP Condition
-DOCSTART- -X- N

microleakage NN Condition
of IN None
Class NNP Condition
II NNP Condition
composite JJ Condition
restorations NNS Condition
. . None
Class NNP Condition
II NNP Condition
preparations NNS Condition
60 CD Size
extracted JJ Condition
teeth NNS Condition
five CD None
groups NNS None
of IN None
12 CD Size
. . None
deep JJ Condition
Class NNP Condition
II NNP Condition
direct JJ Condition
composite JJ Condition
restorations NNS Condition
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
cerebral JJ Condition
palsy NN Condition
: : None
children NNS Age
with IN None
cerebral JJ Condition
palsy NN Condition
. . None
Children NNP Age
between IN None
4 CD Age
and CC Age
18 CD Age
years NNS None
old JJ None
with IN None
cerebral JJ Condition
palsy NN Condition
. . None
Thirty-eight JJ Size
children NNS Age
participated VBN None
. . None
cerebral JJ Condition
palsy NN Condition
children NNS Age
-DOCSTART- -X- N

non-diabetic JJ Condition
chronic JJ Condition
kidney NN Condition
disease NN Condition
: : None
patients NNS None
with IN None
non-diabetic JJ None
chronic JJ None
kidney NN None
disease NN None
. . None
14 CD None
patients NNS None
with IN None
nondiabetic JJ None
chronic JJ None
kidney NN None
disease NN None
with IN None
24-h JJ None
mean JJ None
proteinuria NN None
of IN None
2.01 CD None
g NN None
( ( None
95 CD None
% NN None
CI NNP None
, , None
1.36?2.66 CD None
) ) None
and CC None
estimated VBN None
creatinine JJ None
clearance NN None
of IN None
93?6.8 CD None
ml/min NN None
. . None
The DT None
of IN None
patients NNS None
with IN None
chronic JJ None
proteinuric JJ None
non-diabetic JJ None
kidney NN None
disease NN None
. . None
-DOCSTART- -X- N

hypertension NN Condition
. . None
Twenty CD Size
patients NNS None
with IN None
essential JJ Condition
hypertension NN Condition
-DOCSTART- -X- N

Direct JJ None
trocar NN None
Verres NNP None
needle FW None
laparoscopic JJ Condition
sterilization NN Condition
. . None
randomized JJ None
, , None
prospective JJ None
trial NN None
was VBD None
designed VBN None
to TO None
compare VB None
direct JJ None
trocar NN None
insertion NN None
with IN None
prior JJ None
peritoneal JJ None
insufflation NN None
with IN None
a DT None
Verres NNP None
needle NN None
for IN None
laparoscopic NN Condition
tubal JJ Condition
sterilization NN Condition
. . None
needle JJ None
group NN None
trocar NN None
group NN None
. . None
omental JJ Condition
injuries NNS Condition
-DOCSTART- -X- N

chronic JJ Condition
cancer NN Condition
pain NN Condition
in IN None
adults NNS Age
: : None
Outpatients NNS None
with IN None
cancer NN None
were VBD None
eligible JJ None
for IN None
the DT None
study NN None
if IN None
they PRP None
were VBD None
aged VBN None
> JJ None
-18 CD None
years NNS None
and CC None
had VBD None
chronic VBN None
( ( None
duration NN None
, , None
> NNP None
/= VBZ None
3 CD None
months NNS None
) ) None
moderate VBP None
to TO None
severe VB None
cancer-related JJ None
pain NN None
( ( None
score NN None
on IN None
10-cm JJ None
visual JJ None
analog NN None
scale NN None
[ NNP None
VAS NNP None
] NNP None
, , None
> VBD None
3 CD None
cm NN None
[ NN None
moderate JJ None
] NN None
; : None
score NN None
on IN None
a DT None
4-point JJ None
verbal JJ None
pain-intensity NN None
scale NN None
, , None
> VBZ None
1 CD None
[ NN None
moderate JJ None
] NN None
) ) None
. . None
the DT None
121 CD None
patients NNS None
who WP None
participated VBD None
, , None
Of IN None
the DT None
total JJ None
number NN None
of IN None
cases NNS None
, , None
59 CD None
% NN None
were VBD None
aged VBN None
60 CD None
to TO None
89 CD None
years NNS None
, , None
and CC None
55 CD None
% NN None
were VBD None
men NNS None
. . None
these DT None
patients NNS None
with IN None
moderate JJ None
or CC None
severe JJ None
, , None
chronic JJ None
, , None
cancer-related JJ None
pain NN None
. . None
-DOCSTART- -X- N

migraine NN Condition
with IN Condition
aura NN Condition
: : None
patients NNS None
who WP None
had VBD None
at IN None
least JJS None
one CD Condition
aura NN Condition
attack NN Condition
per IN Condition
month NN Condition
during IN None
the DT None
past JJ None
3 CD None
months NNS None
. . None
39 CD Size
patients NNS None
were VBD None
included VBN None
in IN None
the DT None
study NN None
, , None
of IN None
whom WP None
31 CD Size
were VBD None
included VBN None
in IN None
the DT None
statistical JJ None
analysis NN None
of IN None
efficacy NN None
. . None
-DOCSTART- -X- N

human JJ None
volunteers NNS None
. . None
American NNP None
Society NNP None
of IN None
Anesthesiologists NNP None
physical JJ Condition
status NN Condition
1 CD Condition
( ( None
n JJ None
= NNP None
17 CD Size
) ) None
volunteers NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
HCV NNP Condition
genotype NN Condition
1 CD Condition
infection NN None
treated VBN None
with IN None
peginterferon NN None
alpha-2a JJ None
plus CC None
ribavirin JJ None
. . None
patients NNS None
with IN None
chronic JJ Condition
hepatitis NN Condition
C NNP Condition
treatment-naive JJ None
patients NNS None
with IN None
HCV NNP None
genotype NN None
1 CD None
infection NN None
enrolled VBN None
in IN None
a DT None
large JJ None
expanded JJ None
access NN None
programme NN None
. . None
Eight NNP Size
hundred VBD Size
and CC Size
ninety-one JJ Size
patients NNS None
treated VBD None
for IN None
48 CD None
weeks NNS None
with IN None
an DT None
initial JJ None
ribavirin NN None
dose NN None
of IN None
800 CD None
or CC None
1000/1200 CD None
mg/day NNS None
genotype JJ None
1 CD None
patients NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
obstructive JJ Condition
pulmonary JJ Condition
disease NN Condition
at IN None
the DT None
stable JJ None
phase NN None
] NNP None
. . None
patients NNS None
with IN None
chronic JJ None
obstructive JJ None
pulmonary JJ None
disease NN None
( ( None
COPD NNP Condition
) ) None
at IN None
the DT None
stable JJ Condition
phase NN Condition
. . None
Thirty-six JJ Size
patients NNS None
with IN None
COPD NNP Condition
patients NNS None
with IN None
COPD NNP None
in IN None
the DT None
stable JJ None
phase NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
mild-to-moderate JJ None
essential JJ None
hypertension NN None
. . None
205 CD None
patients NNS None
from IN None
16 CD None
investigators NNS None
. . None
-DOCSTART- -X- N

gene NN None
in IN None
neonatal JJ Age
screening NN None
for IN None
congenital JJ Condition
adrenal JJ Condition
hyperplasia NN Condition
. . None
neonatal JJ Age
screening NN None
samples NNS None
. . None
603 CD Size
randomly RB None
chosen VBN None
New NNP None
Zealand NNP None
neonates NNS Age
Another DT None
50 CD Size
samples NNS None
from IN None
Swiss NNP None
and CC None
North NNP None
American JJ None
infants NNS None
with IN None
correlative JJ None
hormonal JJ None
New NNP None
Zealanders NNP None
. . None
newborn JJ Age
-DOCSTART- -X- N

partial JJ Condition
thickness NN Condition
burns NNS Condition
thermal JJ Condition
2nd CD Condition
degree NN Condition
burns NNS Condition
partial JJ Condition
thickness NN Condition
burns NNS Condition
. . None
40 CD Size
patients NNS None
received VBD None
either RB None
topical JJ None
treatment NN None
with IN None
Moist NNP None
Exposed VBD None
Burn NNP None
Ointment NNP None
( ( None
MEBO NNP None
) ) None
or CC None
standard JJ None
Flammazine NNP None
treatment NN None
. . None
All DT None
patients NNS None
suffered VBD None
from IN None
partial-thickness JJ None
burn NN None
injuries NNS None
( ( None
< VB None
20 CD None
% NN None
TBSA NNP None
) ) None
. . None
limited JJ Condition
partial JJ Condition
thickness NN Condition
thermal JJ Condition
burns NNS Condition
. . None
-DOCSTART- -X- N

non-diabetic JJ Condition
men NNS Sex
with IN None
hypertension NN Condition
, , None
hypertriglyceridaemia NN Condition
and CC None
central JJ Condition
fat JJ Condition
distribution NN Condition
: : None
non-diabetic JJ Condition
obese JJ Condition
subjects NNS None
with IN None
a DT None
central JJ Condition
fat JJ Condition
distribution NN Condition
non-diabetic JJ Condition
men NNS Sex
( ( None
n=168 NN Size
) ) None
with IN None
a DT None
fasting VBG None
plasma NN None
triglyceride JJ None
concentration NN None
> NN Condition
or CC Condition
=1.7 NN Condition
and CC Condition
< NN Condition
or CC Condition
=6.5 NN Condition
mmol/l NN Condition
, , None
high JJ Condition
blood NN Condition
pressure NN Condition
( ( None
systolic JJ None
> NN None
or CC None
=140 NN None
and CC None
< NN None
or CC None
=180 VB None
and/or JJ None
diastolic JJ None
> NN None
or CC None
=90 NN None
and CC None
< NN None
or CC None
=105 NN None
mmHg NN None
, , None
or CC None
treatment NN None
for IN None
hypertension NN Condition
) ) None
and CC None
a DT None
waist-to-hip JJ Condition
ratio NN Condition
> NN Condition
or CC Condition
=0.95 NN Condition
. . Condition
non-diabetic JJ Condition
subjects NNS None
with IN None
a DT None
central JJ Condition
fat JJ Condition
distribution NN Condition
. . None
-DOCSTART- -X- N

paediatric JJ Condition
tonsillectomy NN Condition
. . Condition
From NNP None
July NNP None
2004 CD None
to TO None
April NNP None
2006 CD None
, , None
80 CD None
patients NNS None
aged VBN None
between IN None
10 CD None
and CC None
15 CD None
years NNS None
, , None
with IN None
tonsillectomy NN None
planned VBN None
for IN None
chronic JJ None
tonsillitis NN None
, , None
were VBD None
included VBN None
in IN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

people NNS None
with IN None
schizophrenia NN Condition
in IN None
Beijing NNP None
, , None
China NNP None
: : None
people NNS None
with IN None
schizophrenia NN None
and CC None
their PRP$ None
families NNS None
sample NN None
of IN None
Chinese JJ None
people NNS None
with IN None
schizophrenia NN None
. . None
large JJ None
hospital NN None
with IN None
a DT None
sample NN None
of IN None
101 CD Size
patients NNS None
with IN None
schizophrenia NN None
and CC None
their PRP$ None
families NNS None
. . None
-DOCSTART- -X- N

inpatient JJ Condition
alcoholics NNS Condition
. . None
inpatient JJ None
alcoholics NNS None
with IN None
nursing NN None
home NN None
residents NNS None
( ( None
NHRs NNP None
) ) None
Fifty NNP None
alcoholic JJ None
inpatients NNS Condition
were VBD Condition
randomly RB Condition
assigned VBN Condition
to TO Condition
the DT Condition
PALS NNP Condition
program NN Condition
( ( Condition
n JJ Condition
= NNP Condition
25 CD Condition
) ) Condition
or CC Condition
to TO Condition
the DT Condition
library NN Condition
for IN Condition
free JJ Condition
reading NN Condition
time NN Condition
( ( Condition
n JJ Condition
= NNP Condition
25 CD Condition
) ) Condition
. . None
-DOCSTART- -X- N

for IN None
tracheal JJ None
intubation NN None
under IN None
general JJ None
anesthesia NN None
with IN None
simulated JJ None
difficult JJ None
airway NN None
. . None
METHODS NNP None
Ninety-four JJ None
subjects NNS None
successfully RB None
completed VBD None
the DT None
trial NN None
. . None
Manual JJ None
simulated JJ None
difficult JJ None
airway NN None
. . None
-DOCSTART- -X- N

patients NNS None
recruited VBN None
into IN None
the DT None
Carvedilol NNP None
or CC None
Metoprolol NNP None
European JJ None
Trial NNP None
( ( None
COMET NNP None
) ) None
. . None
patients NNS None
with IN None
heart NN Condition
failure NN Condition
and CC None
left VBD Condition
ventricular JJ Condition
systolic JJ Condition
dysfunction NN Condition
. . None
Almost NNP None
all DT None
patients NNS None
were VBD None
receiving VBG None
diuretics NNS None
and CC None
ACE NNP None
inhibitors NNS None
with IN None
few JJ None
patients NNS None
taking VBG None
angiotensin JJ None
receptor NN None
blockers NNS None
. . None
-DOCSTART- -X- N

stable JJ None
patients NNS None
with IN None
moderate-to-severe JJ None
chronic JJ Condition
obstructive JJ Condition
pulmonary JJ Condition
disease NN Condition
. . None
chronic JJ None
obstructive JJ None
pulmonary JJ None
disease NN None
( ( None
COPD NNP Condition
) ) None
114 CD Size
patients NNS None
with IN None
COPD NNP Condition
of IN None
moderate-to-severe JJ None
degree NN None
. . None
moderate-to-severe JJ Condition
COPD NNP Condition
patients NNS None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
essential JJ Condition
hypertension NN Condition
. . None
patients NNS None
with IN None
essential JJ None
hypertension NN None
-DOCSTART- -X- N

Norfloxacin NNP None
modulates VBZ None
the DT None
inflammatory JJ None
response NN None
and CC None
directly RB None
affects VBZ None
neutrophils NNS None
in IN None
patients NNS None
with IN None
decompensated JJ Condition
cirrhosis NN Condition
. . None
Patients NNPS None
with IN None
cirrhosis NN Condition
undergoing VBG None
selective JJ None
intestinal JJ None
decontamination NN None
with IN None
norfloxacin JJ None
Thirty-one CD Size
patients NNS None
with IN None
cirrhosis NN None
receiving VBG None
norfloxacin NN None
( ( None
400 CD None
mg/day NN None
) ) None
were VBD None
included VBN None
. . None
Fifty-nine JJ None
ascitic JJ None
fluid NN None
samples NNS None
patients NNS None
with IN None
cirrhosis NN Condition
. . None
-DOCSTART- -X- N

anemic JJ Condition
cancer NN Condition
patients NNS Condition
on IN Condition
combination NN Condition
chemotherapy NN Condition
. . None
Patients NNPS None
with IN None
advanced JJ None
cancer NN None
frequently RB None
experience VBZ None
clinically RB None
significant JJ None
anemia NN None
cancer NN None
patients NNS None
. . None
patients NNS None
with IN None
advanced JJ None
cancer NN None
who WP None
were VBD None
receiving VBG None
myelosuppressive JJ None
chemotherapy NN None
( ( None
excluding VBG None
cisplatin NN None
) ) None
. . None
153 CD Size
anemic JJ None
cancer NN None
patients NNS None
receiving VBG Condition
cyclic JJ Condition
combination NN Condition
chemotherapy NN Condition
patients NNS None
rHuEPO-treated JJ Condition
group NN None
placebo-treated JJ Condition
group NN None
rHuEPO-treated JJ None
patients NNS None
placebo-treated JJ None
patients NNS None
rHuEPO-treated JJ None
patients NNS None
rHuEPO-treated JJ None
group NN None
. . None
-DOCSTART- -X- N

glucose JJ Condition
tolerance NN Condition
. . None
type NN Condition
2 CD Condition
diabetes NNS Condition
. . None
15 CD Size
overweight JJ Condition
men NNS Sex
. . None
-DOCSTART- -X- N

healthy JJ Condition
subjects NNS None
. . None
Thirteen NNP Size
healthy JJ None
human JJ None
volunteers NNS None
( ( None
6 CD Sex
men NNS Sex
and CC Sex
7 CD Sex
women NNS Sex
, , None
aged VBN None
20-28 CD Age
years NNS None
) ) None
-DOCSTART- -X- N

large JJ Condition
bowel NN Condition
carcinoma NN Condition
-- : None
fluorouracil NN None
advanced JJ Condition
measurable JJ Condition
metastatic JJ Condition
large JJ Condition
bowel NN Condition
carcinoma NN Condition
6/32 CD None
( ( None
19 CD None
% NN None
) ) None
for IN None
FU NNP None
+ NNP None
HU NNP None
and CC None
5/32 CD None
( ( None
16 CD None
% NN None
) ) None
for IN None
MOF-Strep NNP None
; : None
patients NNS None
who WP None
received VBD None
-DOCSTART- -X- N

dyspnoea NN Condition
in IN None
primary JJ None
care NN None
. . None
heart NN None
failure NN None
in IN None
primary JJ None
care NN None
B-type NNP None
natriuretic JJ None
peptide NN None
( ( None
BNP NNP None
) ) None
levels NNS None
. . None
Twenty-nine JJ Size
primary JJ None
care NN None
physicians NNS None
in IN None
Switzerland NNP None
and CC None
Germany NNP None
coordinated VBN None
by IN None
the DT None
University NNP None
Hospital NNP None
Basel NNP None
, , None
Switzerland NNP None
. . None
total NN None
of IN None
323 CD Size
consecutive JJ None
patients NNS None
presenting VBG None
with IN None
dyspnoea NN Condition
. . None
-DOCSTART- -X- N

self-injurious JJ None
and CC None
autistic JJ None
behavior NN None
in IN None
mentally RB None
retarded JJ None
adults NNS None
. . None
SIB NNP Condition
and CC Condition
autism NN Condition
in IN None
mentally RB None
retarded JJ None
adults NNS None
. . None
Thirty-three NNP Size
mentally RB None
retarded VBD None
adults NNS Age
with IN None
autism NN None
and/or NN None
SIB NNP None
participated VBD None
in IN None
double-blind NN None
, , None
placebo-controlled JJ None
crossover NN None
studies NNS None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
attention NN Condition
deficit NN Condition
hyperactivity NN Condition
disorder NN Condition
. . None
children NNS Age
with IN None
attention NN Condition
deficit NN Condition
hyperactivity NN Condition
disorder NN Condition
( ( None
ADHD NNP Condition
) ) None
. . None
Forty NNP Size
children NNS Age
with IN None
ADHD NNP Condition
-DOCSTART- -X- N

Swedish JJ None
adolescents NNS Age
. . None
1996 CD None
a DT None
randomized JJ None
sample NN None
of IN None
4,020 CD Size
Swedish JJ None
adolescents NNS Age
from IN None
three CD None
birth NN None
cohorts NNS None
A DT None
total NN None
of IN None
2,615 CD Size
questionnaires NNS None
were VBD None
returned VBN None
. . None
Girls NNP Sex
boys NNS Sex
-DOCSTART- -X- N

volunteers NNS None
at IN None
a DT None
low JJ Condition
risk NN Condition
of IN None
infection NN None
with IN None
hepatitis NN Condition
B NNP Condition
virus NN Condition
. . None
471 CD Size
healthy JJ Condition
human JJ None
volunteers NNS None
, , None
who WP None
, , None
both DT None
in IN None
their PRP$ None
occupations NNS None
and CC None
in IN None
their PRP$ None
private JJ None
lives NNS None
, , None
had VBD None
been VBN None
at IN None
minimal JJ Condition
risk NN Condition
of IN None
being VBG None
infected VBN None
with IN None
hepatitis NN Condition
B NNP Condition
virus NN Condition
. . None
-DOCSTART- -X- N

adults NNS Age
with IN None
acute JJ Condition
lymphoblastic JJ Condition
leukemia NN Condition
: : None
adults NNS Age
with IN None
acute JJ Condition
lymphoblastic JJ Condition
leukemia NN Condition
( ( None
ALL DT Condition
) ) None
patients NNS None
with IN None
Philadelphia NNP Condition
chromosome NN Condition
( ( Condition
Ph NNP Condition
) ) Condition
-positive VBP Condition
ALL NNP None
. . None
accrued VBD None
patients NNS None
from IN None
August NNP None
1996 CD None
to TO None
October NNP None
2004 CD None
. . None
median JJ None
patient NN None
age NN None
was VBD None
43 CD Age
years NNS None
. . None
Responses NNS None
were VBD None
evaluated VBN None
in IN None
164 CD Size
patients NNS None
. . None
patients NNS None
-DOCSTART- -X- N

moderate JJ Condition
asthma NN Condition
. . None
asthma NN Condition
patients NNS None
with IN None
moderate JJ Condition
asthma NNS Condition
previously RB None
treated VBN None
with IN None
an DT None
inhaled JJ None
corticosteroid NN None
. . None
342 CD Size
adolescent NN Age
and CC None
adult NN Age
patients NNS None
with IN None
moderate JJ Condition
asthma NNS Condition
[ RB None
forced VBD None
expiratory JJ None
volume NN None
in IN None
1 CD None
second JJ None
( ( None
FEV1 NNP None
) ) None
between IN None
50 CD None
% NN None
and CC None
80 CD None
% NN None
of IN None
predicted JJ None
] NNP None
treated VBD None
previously RB None
by IN None
beclomethasone NN None
dipropionate NN None
or CC None
triamcinolone NN None
acetonide RB None
. . None
patients NNS None
with IN None
moderate JJ Condition
asthma NNS Condition
. . None
-DOCSTART- -X- N

wives NNS Sex
of IN None
men NNS Sex
with IN None
prostate NN Condition
cancer NN Condition
. . None
wives NNS Sex
of IN None
men NNS Sex
diagnosed VBN None
with IN None
prostate JJ Condition
cancer NN Condition
Sixty NNP Size
wives NNS Sex
spouses NNS Sex
of IN None
men NNS Sex
with IN None
prostate NN Condition
cancer NN Condition
-DOCSTART- -X- N

stroke NN Condition
: : None
Tinzaparin NNP None
in IN None
Acute NNP Condition
Ischaemic NNP Condition
Stroke NNP Condition
Trial NNP None
( ( None
TAIST NNP None
) ) None
. . None
High NNP Condition
blood NN Condition
pressure NN Condition
( ( None
BP NNP None
) ) None
in IN None
acute JJ Condition
stroke NN Condition
using VBG None
data NNS None
from IN None
TAIST NNP None
trial NN None
. . None
high JJ None
systolic JJ None
BP NNP None
, , None
mean JJ None
arterial JJ None
pressure NN None
, , None
pulse JJ None
pressure NN None
, , None
and CC None
BP NNP None
variability NN None
. . None
acute JJ Condition
ischemic JJ Condition
stroke NN Condition
. . None
-DOCSTART- -X- N

Three CD None
groups NNS None
of IN None
six CD Size
women NNS Sex
were VBD None
admitted VBN None
and CC None
randomly RB None
assigned VBN None
to TO None
use VB None
Acidform NNP None
with IN None
0 CD None
% NN None
, , None
2.5 CD None
% NN None
, , None
and CC None
5 CD None
% NN None
N-9 NNP None
. . None
10 CD Size
volunteers NNS None
. . None
-DOCSTART- -X- N

Japanese JJ None
smokers NNS None
: : None
Japanese JJ None
smokers NNS None
. . None
eight CD Sex
male JJ Sex
habitual JJ Sex
smokers NNS Sex
Japanese JJ None
habitual JJ None
smokers NNS None
. . None
-DOCSTART- -X- N

screening VBG None
normally RB Condition
intelligent JJ Condition
persons NNS None
with IN None
pervasive JJ Condition
developmental NN Condition
disorders NNS Condition
. . None
25 CD Condition
normally RB Condition
intelligent JJ Condition
high-functioning JJ Condition
pervasive JJ Condition
developmental NN Condition
disorder NN Condition
( ( None
HPDD NNP Condition
) ) None
patients NNS None
( ( None
mean JJ None
age NN None
, , None
24.2 CD Age
years NNS Age
; : None
24 CD Condition
male NN Age
, , None
one CD Condition
female NN Age
) ) None
and CC None
215 CD Condition
controls NNS None
( ( None
mean JJ None
age NN None
, , None
30.4 CD Age
years NNS Age
; : None
86 CD Condition
male NN Age
, , None
129 CD Condition
female NN Age
) ) None
randomly RB None
selected VBN None
from IN None
the DT None
general JJ None
population NN None
. . None
-DOCSTART- -X- N

33 CD Size
patients NNS None
with IN None
pulmonary JJ Condition
hypertension NN Condition
. . None
33 CD Size
age- JJ None
and CC None
sex-matched JJ None
control NN None
subjects NNS None
. . None
-DOCSTART- -X- N

adult NN Age
autistic JJ Condition
disorder NN Condition
. . None
repetitive JJ None
behaviors NNS None
in IN None
adult NN Age
autistic JJ Condition
patients NNS None
. . None
Eleven NNP Size
adult NN Age
patients NNS None
with IN None
autism NN Condition
or CC None
Asperger NNP Condition
's POS Condition
disorder NN Condition
were VBD None
randomized VBN None
-DOCSTART- -X- N

a DT None
mildly RB Condition
dehydrated JJ Condition
state NN Condition
. . None
athletes NNS None
mildly RB None
hypohydrated VBN None
( ( None
HYPO NNP Condition
) ) None
state NN None
Ten CD None
recreational JJ None
athletes NNS None
( ( None
6 CD None
women NNS None
, , None
4 CD None
men NNS None
; : None
71.9 CD None
? . None
4.6 CD None
kg NN None
, , None
25.2 CD None
? . None
0.9 CD None
years NNS None
) ) None
participated VBD None
in IN None
demonstrated VBD None
that IN None
mildly RB None
HYPO NNP None
subjects NNS None
-DOCSTART- -X- N

patients NNS None
undergoing VBG None
hip JJ Condition
fracture NN Condition
surgery NN Condition
. . None
patients NNS None
undergoing JJ None
surgery NN Condition
for IN None
acute JJ Condition
hip NN Condition
fracture NN Condition
. . None
A NNP None
consecutive JJ None
cohort NN None
of IN None
patients NNS None
( ( None
n JJ None
= NN None
200 CD Size
, , None
68 CD Size
men NNS Sex
) ) None
referred VBD None
to TO None
acute VB Condition
surgical JJ Condition
correction NN None
of IN None
hip NN Condition
fracture NN Condition
was VBD None
studied VBN None
. . None
The DT None
age NN None
of IN None
the DT None
patients NNS None
ranged VBD None
from IN None
32 CD Age
to TO Age
98 CD Age
years NNS None
( ( None
mean NN None
, , None
80.8 CD Age
years NNS Age
) ) None
, , None
and CC None
65 CD Size
patients NNS None
had VBD None
a DT None
history NN None
of IN None
coronary JJ Condition
artery NN Condition
disease NN Condition
. . None
-DOCSTART- -X- N

surgical JJ None
patients NNS None
with IN None
aneurysmal JJ None
subarachnoid JJ None
hemorrhage NN None
. . None
among IN None
patients NNS None
enrolled VBN None
in IN None
the DT None
Intraoperative NNP None
Hypothermia NNP None
for IN None
Aneurysm NNP None
Surgery NNP None
Trial NNP None
. . None
One CD None
thousand NN None
patients NNS None
with IN None
initial JJ None
World NNP None
Federation NNP None
of IN None
Neurological NNP None
Surgeons NNP None
grades NNS None
of IN None
I PRP None
to TO None
III NNP None
undergoing VBG None
clipping NN None
of IN None
intracranial JJ None
aneurysms NNS None
after IN None
subarachnoid JJ None
hemorrhage NN None
were VBD None
randomized VBN None
to TO None
intraoperative VB None
normothermia NN None
( ( None
36 CD None
degrees NNS None
C-37 JJ None
degrees NNS None
C NNP None
) ) None
or CC None
hypothermia NN None
( ( None
32.5 CD None
degrees NNS None
C-33.5 JJ None
degrees NNS None
C NNP None
) ) None
. . None
surgical JJ None
subarachnoid JJ None
hemorrhage NN None
patients NNS None
-DOCSTART- -X- N

drug NN None
effects NNS None
and CC None
abuse NN None
liability NN None
in IN None
nondependent JJ Condition
subjects NNS None
. . None
15 CD Size
male NN Sex
, , None
experienced VBD None
, , None
intermittent JJ None
nontherapeutic JJ None
drug NN Condition
users NNS Condition
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
receiving VBG None
targeted VBN None
interventions NNS None
on IN None
joint JJ None
attention NN None
and CC None
play NN None
. . None
children NNS None
with IN None
an DT None
autism NN Condition
spectrum NN Condition
disorder NN Condition
( ( None
ASD NNP Condition
) ) None
over IN None
a DT None
5-year JJ None
period NN None
after IN None
receiving VBG None
targeted VBD None
early JJ None
interventions NNS None
that WDT None
focused VBD None
on IN None
joint JJ None
attention NN None
and CC None
play NN None
skills NNS None
. . None
Forty NNP Size
children NNS None
from IN None
the DT None
original JJ None
study NN None
( ( None
n JJ None
= NNP None
58 CD Size
) ) None
had VBD None
complete JJ None
data NNS None
at IN None
the DT None
5-year JJ None
follow-up NN None
. . None
children NNS Age
who WP None
participated VBD None
in IN None
preschool NN None
early JJ None
interventions NNS None
aimed VBN None
at IN None
targeting VBG None
core NN Condition
developmental NN Condition
difficulties NNS Condition
. . None
-DOCSTART- -X- N

dyspnoeic JJ Condition
patients NNS None
100 CD Size
consecutive JJ None
patients NNS None
patients NNS None
with IN None
severe JJ Condition
pulmonary JJ Condition
disease NN Condition
-DOCSTART- -X- N

nursing NN Condition
home NN Condition
patients NNS Condition
: : None
nursing JJ None
home NN None
patients NNS None
. . None
624 CD Size
nursing NN None
home NN None
patients NNS None
with IN None
dementia NN Condition
, , None
446 CD Size
completed VBD None
follow-up JJ None
assessments NNS None
. . None
-DOCSTART- -X- N

One CD Size
hundred CD Size
and CC Size
ten VB Size
consecutive JJ None
patients NNS None
were VBD None
evaluated VBN None
. . None
premalignant JJ Condition
changes NNS Condition
of IN Condition
the DT Condition
cervix NN Condition
uteri NN Condition
-DOCSTART- -X- N

patients NNS None
undergoing VBG None
ambulatory JJ Condition
cosmetic JJ Condition
surgery NN Condition
. . Condition
postoperative JJ Condition
nausea NN Condition
and CC Condition
vomiting NN Condition
( ( None
PONV NNP Condition
) ) None
. . None
Academic NNP None
hospital NN None
. . None
126 CD Size
ASA NNP Condition
physical JJ Condition
status NN Condition
I PRP Condition
and CC Condition
II NNP Condition
patients NNS Condition
undergoing VBG None
outpatient JJ Condition
plastic NN Condition
surgery NN Condition
with IN None
three CD None
or CC None
more JJR None
risk NN None
factors NNS None
for IN None
PONV NNP Condition
. . None
patients NNS None
at IN None
high JJ None
risk NN None
for IN None
PONV NNP None
undergoing JJ None
outpatient NN None
plastic NN None
surgery NN None
-DOCSTART- -X- N

proximal JJ Condition
interphalangeal NN Condition
joint NN Condition
in IN None
the DT None
horse NN None
Eight JJ Size
horses NNS None
-DOCSTART- -X- N

Asymptomatic JJ Condition
patients NNS None
admitted VBN None
to TO None
the DT None
physical JJ None
check-up JJ None
department NN None
of IN None
Buddhist NNP None
Dalin NNP None
Tzu NNP None
Chi NNP None
General NNP None
Hospital NNP None
Between NNP None
April NNP None
2005 CD None
and CC None
February NNP None
2006 CD None
, , None
a DT None
total NN None
of IN None
918 CD Size
patients NNS None
were VBD None
enrolled VBN None
. . None
-DOCSTART- -X- N

children NNS Age
male JJ Sex
relatives NNS None
. . None
children NNS Age
family NN None
members NNS None
. . None
Parents NNS None
of IN None
381 CD Size
girls NNS Sex
and CC None
375 CD Size
boys NNS Sex
age NN None
8-12 JJ Age
y NN None
completed VBN None
family NN None
history NN None
questionnaires NNS None
. . None
children NNS Age
-DOCSTART- -X- N

traumatic JJ Condition
hyphema NN Condition
. . None
One CD Size
hundred VBD Size
twelve NN Size
patients NNS None
who WP None
sustained VBD None
hyphema NN Condition
after IN Condition
blunt NN Condition
trauma NN Condition
were VBD None
enrolled VBN None
Blacks NNS None
comprised VBD None
53 CD None
% NN None
of IN None
the DT None
study NN None
population NN None
, , None
and CC None
the DT None
mean JJ None
age NN None
of IN None
the DT None
patients NNS None
was VBD None
23.5 CD Age
years NNS None
. . None
-DOCSTART- -X- N

radiocontrast-induced JJ None
nephropathy NN None
. . None
patients NNS None
undergoing VBG None
coronary JJ None
procedures NNS None
. . None
single-center JJ None
patients NNS Condition
undergoing VBG Condition
cardiovascular JJ Condition
procedures NNS Condition
. . Condition
We PRP None
prospectively RB None
enrolled VBD None
264 CD None
patients NNS None
who WP None
were VBD None
scheduled VBN None
for IN None
cardiovascular JJ None
procedures NNS None
and CC None
had VBD None
a DT None
baseline JJ None
creatinine NN None
level NN None
> VBD None
1.2 CD None
mg/dL NN None
. . None
-DOCSTART- -X- N

new JJ None
admissions NNS None
. . None
individuals NNS None
in IN None
the DT None
transitional JJ None
period NN None
following VBG None
a DT None
return NN None
to TO None
the DT None
community NN None
. . None
individuals NNS None
newly RB None
admitted VBN None
to TO None
nursing VBG Condition
homes NNS Condition
and CC None
worked VBD None
with IN None
a DT None
family NN None
caregiver NN None
to TO None
develop VB None
and CC None
implement VB None
a DT None
nursing NN None
home NN None
discharge NN None
plan NN None
. . None
intervention NN None
group NN None
( ( None
n JJ None
= NNP None
33 CD Size
) ) None
control NN None
group NN None
( ( None
n JJ None
= NNP None
29 CD Size
) ) None
-DOCSTART- -X- N

commercial JJ None
beef NN None
cattle NNS None
at IN None
housing NN None
. . None
commercial JJ None
beef NN None
cattle NNS None
with IN None
three CD None
fluke NNS None
and CC None
worm VB None
combination NN None
products NNS None
with IN None
different JJ None
administration NN None
profiles NNS None
. . None
Young NNP None
beef NN None
cattle NNS None
( ( None
n JJ None
= NNP None
270 CD None
) ) None
weighing VBG None
approximately RB None
400 CD None
kg NNS None
were VBD None
allocated VBN None
to TO None
batches NNS None
of IN None
five CD None
-DOCSTART- -X- N

pediatric JJ Age
dental JJ Condition
patients NNS Condition
. . None
children NNS Age
undergoing VBG None
dental JJ Condition
extractions NNS Condition
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
steroid-dependent JJ Condition
and CC None
frequently RB Condition
relapsing VBG Condition
idiopathic JJ Condition
nephrotic JJ Condition
syndrome NN Condition
: : None
patients NNS None
with IN None
steroid-dependent JJ Condition
or CC None
frequently RB Condition
relapsing VBG Condition
nephrotic JJ Condition
syndrome NN Condition
( ( None
NS NNP Condition
) ) None
. . None
adults NNS Age
and CC None
children NNS Age
. . None
in IN None
Italy NNP None
. . None
Seventy-three JJ Size
patients NNS None
with IN None
steroid-sensitive JJ Condition
idiopathic JJ Condition
NS NNP Condition
admitted VBD None
to TO None
the DT None
study NN None
-DOCSTART- -X- N

90 CD Size
patients NNS None
scheduled VBN None
for IN None
minor JJ Condition
gynaecological JJ Condition
( ( None
hysteroscopy NN Condition
) ) None
or CC None
urological JJ Condition
( ( None
ureteroscopy JJ Condition
) ) None
procedures NNS None
planned VBN None
to TO None
last JJ None
1-2 JJ None
h NN None
under IN None
sevoflurane NN None
anaesthesia NN None
with IN None
spontaneous JJ None
ventilation NN None
of IN None
the DT None
lungs NNS None
via IN None
a DT None
laryngeal JJ None
mask NN None
airway NN None
. . None
patients NNS None
who WP None
experienced VBD None
postoperative JJ Condition
nausea NN Condition
and CC None
vomiting NN Condition
in IN None
the DT None
first JJ None
24 CD None
h NN None
( ( None
30 CD None
% NN None
and CC None
27 CD None
% NN None
for IN None
the DT None
midazolam NN None
and CC None
ondansetron NN None
groups NNS None
, , None
respectively RB None
) ) None
were VBD None
similar JJ None
in IN None
the DT None
two CD None
groups NNS None
. . None
patients NNS None
' POS None
underlying JJ None
risks NNS None
( ( None
midazolam JJ None
group NN None
: : None
p NN None
= VBZ None
0.018 CD None
; : None
ondansetron VBN None
group NN None
: : None
p NN None
= VBZ None
0.017 CD None
) ) None
. . None
-DOCSTART- -X- N

small JJ None
group NN None
student NN None
interaction NN None
for IN None
children NNS None
with IN None
autism NN Condition
and CC None
developmental JJ Condition
disabilities NNS Condition
. . None
24 CD Size
elementary JJ Age
age NN Age
students NNS None
with IN None
autism NN Condition
and CC None
developmental JJ Condition
disabilities NNS Condition
. . None
-DOCSTART- -X- N

1999 CD None
MONICA NNP None
sample NN None
from IN None
northern JJ None
Sweden NNP None
. . None
MONICA NNP None
sample NN None
of IN None
6000 CD Size
subjects NNS None
from IN None
a DT None
geographically RB None
defined VBN None
population NN None
in IN None
northern JJ None
Sweden NNP None
, , None
regarding VBG None
indications NNS None
for IN None
treatment NN None
, , None
target VB None
blood NN None
pressure NN None
and CC None
risk NN None
distribution NN None
. . None
drug-treated JJ Condition
hypertension NN Condition
. . None
untreated JJ Condition
subjects NNS None
low- JJ None
medium- NN None
high- NN None
very-high-risk JJ None
group NN None
. . None
those DT None
aged VBN None
45-54 CD Age
subjects NNS None
aged VBN Age
below IN Age
60 CD Age
-DOCSTART- -X- N

previously RB None
treated VBN None
patients NNS None
with IN None
refractory JJ Condition
advanced JJ Condition
non-small-cell JJ Condition
lung NN Condition
cancer NN Condition
: : None
patients NNS None
with IN None
locally RB Condition
advanced JJ Condition
or CC Condition
metastatic JJ Condition
non-small-cell JJ Condition
lung NN Condition
cancer NN Condition
. . None
1692 CD Size
patients NNS None
who WP None
were VBD None
refractory JJ Condition
to TO Condition
or CC Condition
intolerant VB Condition
of IN None
their PRP$ None
latest JJS Condition
chemotherapy NN Condition
regimen NNS None
1129 CD Size
patients NNS None
were VBD None
assigned VBN None
gefitinib NNS None
and CC None
563 CD Size
placebo NN None
. . None
812 CD Size
patients NNS None
with IN None
adenocarcinoma NN Condition
never-smokers NNS None
Asian JJ None
origin NN None
never-smokers NNS None
and CC None
patients NNS None
of IN None
Asian JJ None
origin NN None
. . None
-DOCSTART- -X- N

healthy JJ Condition
young JJ Age
adults NNS Age
. . None
Sixty-five JJ Size
healthy JJ Condition
adults NNS Age
aged VBD None
18-29yrs JJ Age
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
: : None
Forty NNP Size
outpatients NNS None
aged VBD None
4 CD Age
to12 NN Age
years NNS None
, , None
who WP None
were VBD None
diagnosed VBN None
with IN None
autism NN Condition
spectrum NN Condition
disorders NNS Condition
based VBN None
on IN None
the DT None
Diagnostic NNP None
and CC None
Statistical NNP None
Manual NNP None
of IN None
Mental NNP None
Disorders NNP None
, , None
Fourth NNP None
Edition NNP None
, , None
Text NNP None
Revision NNP None
criteria NNS None
-DOCSTART- -X- N

unexpected JJ None
perturbations NNS None
during IN None
human JJ None
walking NN None
. . None
healthy JJ Condition
adults NNS Age
. . None
-DOCSTART- -X- N

subarachnoid NN Condition
and CC None
intraventricular JJ Condition
cysticercosis NN Condition
. . None
Thirty-six JJ Size
patients NNS None
with IN None
subarachnoid JJ Condition
and CC None
intraventricular JJ Condition
cysticercosis NN Condition
-DOCSTART- -X- N

patients NNS None
undergoing VBG None
ACL NNP Condition
reconstruction NN Condition
. . None
107 CD Size
American JJ None
Society NNP None
of IN None
Anaesthesiologists NNP None
physical JJ None
status NN None
grade NN None
I PRP None
and CC None
II NNP None
patients NNS None
between IN None
18 CD Age
and CC Age
65 CD Age
years NNS None
of IN None
age NN None
who WP None
were VBD None
scheduled VBN None
to TO None
undergo VB None
elective JJ Condition
anterior JJ Condition
crucial JJ Condition
ligament NN Condition
( ( Condition
ACL NNP Condition
) ) Condition
reconstruction NN Condition
with IN None
hamstring VBG None
autografts NNS None
were VBD None
enrolled VBN None
in IN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

cesarean JJ Condition
delivery NN Condition
: : None
primary JJ Condition
and CC None
repeat JJ Condition
cesarean JJ Condition
deliveries NNS Condition
258 CD Size
women NNS Sex
undergoing VBG None
primary JJ None
and CC None
repeat JJ None
cesarean JJ None
deliveries NNS None
at IN None
32 CD None
weeks NNS None
of IN None
gestation NN None
or CC None
more JJR None
to TO None
creation NN None
( ( None
n=131 JJ Size
) ) None
or CC None
omission NN None
( ( None
n=127 JJ Size
) ) None
of IN None
the DT None
bladder NN None
flap NN None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
myeloid NN Condition
leukemia NN Condition
in IN None
the DT None
chronic JJ Condition
phase NN Condition
: : None
patients NNS None
with IN None
chronic JJ Condition
myeloid NN Condition
leukemia NN Condition
treated VBN None
by IN None
allogeneic JJ Condition
marrow NN Condition
transplantation NN Condition
while IN None
in IN None
the DT None
chronic JJ Condition
phase NN Condition
. . None
Fifty-seven JJ Size
patients NNS None
patients NNS None
receiving VBG None
the DT None
higher JJR None
dose NN None
of IN None
total JJ None
body NN None
irradiation NN None
-DOCSTART- -X- N

pharmacokinetic JJ None
( ( None
PK NNP None
) ) None
BDDrFVIII NNP None
formulations NNS None
in IN None
patients NNS None
with IN None
haemophilia PDT Condition
A DT Condition
series NN None
of IN None
blood NN None
samples NNS None
were VBD None
collected VBN None
over IN None
a DT None
period NN None
of IN None
48 CD None
h NN None
after IN None
i.v NN None
. . None
administration NN None
of IN None
each DT None
of IN None
the DT None
FVIII NNP None
preparations NNS None
. . None
-DOCSTART- -X- N

children NNS None
with IN None
autism NN None
children NNS None
with IN None
autism NN None
47 CD None
teachers NNS None
and CC None
children NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
hip JJ Condition
osteoarthritis NN Condition
: : None
patients NNS None
with IN None
hip NN None
osteoarthritis NN None
( ( None
OA NNP Condition
) ) None
. . None
patients NNS None
from IN None
hospitals NNS None
, , None
primary JJ None
health NN None
care NN None
and CC None
advertisement NN None
, , None
Oslo NNP None
, , None
Norway NNP None
. . None
109 CD Size
patients NNS None
with IN None
radiographic JJ None
and CC None
symptomatic JJ None
hip NN None
OA NNP None
with IN None
mild NN None
to TO None
moderate VB None
symptoms NNS None
. . None
-DOCSTART- -X- N

children NNS Age
with IN None
systemic JJ Condition
ventricular JJ Condition
dysfunction NN Condition
treated VBN None
with IN None
carvedilol NN None
. . None
adults NNS Age
and CC None
children NNS Age
. . None
in IN None
a DT None
population NN None
of IN None
children NNS Age
with IN None
systemic JJ Condition
ventricular JJ Condition
dysfunction NN Condition
and CC None
symptomatic JJ None
heart NN None
failure NN None
treated VBN None
with IN None
carvedilol NN None
or CC None
placebo NN None
. . None
Pediatric NNP None
Carvedilol NNP None
Trial NNP None
( ( None
PCT NNP None
) ) None
participants NNS None
( ( None
carvedilol JJ None
n RB None
= JJ None
161 CD None
; : None
placebo NN None
n IN None
= $ None
55 CD None
) ) None
children NNS None
treated VBD None
with IN None
carvedilol NN None
carvedilol NN None
group NN None
. . None
children NNS None
-DOCSTART- -X- N

73 CD Size
hypertensives NNS Condition
of IN None
a DT None
medicamentously RB None
stabilized VBN None
CNT-group NNP None
group NN None
of IN None
the DT None
same JJ None
size NN None
of IN None
patients NNS None
with IN None
hypertension NN Condition
who WP None
were VBD None
managed VBN None
exclusively RB None
medicamentously RB None
hypertensives NNS Condition
-DOCSTART- -X- N

abdominal JJ Condition
hysterectomies NNS Condition
. . None
total JJ Condition
abdominal JJ Condition
hysterectomy NN Condition
operations NNS None
. . None
We PRP None
conducted VBD None
this DT None
randomized VBN None
controlled VBD None
clinical JJ None
study NN None
on IN None
61 CD Size
patients NNS None
. . None
The DT None
study NN None
was VBD None
conducted VBN None
in IN None
the DT None
operation NN None
room NN None
, , None
post-anesthesia JJ None
care NN None
unit NN None
, , None
and CC None
inpatient JJ None
clinic NN None
. . None
61 CD None
patients NNS None
into IN None
control NN None
group NN None
( ( None
group NN None
C NNP None
) ) None
, , None
block NN None
group NN None
( ( None
group NN None
B NNP None
) ) None
and CC None
dexketoprofen-block JJ None
group NN None
( ( None
group NN None
DB NNP None
) ) None
-DOCSTART- -X- N

normotensive JJ Condition
patients NNS None
. . None
Sixty-six JJ Size
patients NNS None
with IN None
American JJ None
Society NNP None
of IN None
Anesthesiologists NNP None
( ( Condition
ASA NNP Condition
) ) Condition
physical JJ Condition
status NN Condition
class NN Condition
I PRP Condition
who WP None
required VBD None
tracheal JJ Condition
intubation NN Condition
for IN None
elective JJ None
surgery NN None
-DOCSTART- -X- N

lipopolysaccharide-induced JJ Condition
acute NN Condition
lung NN Condition
injury NN Condition
acute JJ Condition
lung NN Condition
injury NN Condition
. . None
rat NN None
72 CD Size
rats NNS None
were VBD None
randomly RB None
allocated VBN None
to TO None
receive VB None
HBO NNP None
or CC None
air NN None
treatment NN None
. . None
rats NNS None
rats NNS None
septic JJ Condition
rats NNS Condition
. . None
-DOCSTART- -X- N

Patients NNP None
scheduled VBD None
to TO None
undergo VB None
ESD NNP None
for IN None
early JJ Condition
gastric JJ Condition
cancer NN Condition
or CC Condition
adenoma NN Condition
were VBD None
randomly RB None
assigned VBN None
to TO None
sedation NN None
with IN None
midazolam NN None
or CC None
propofol NN None
, , None
and CC None
consciousness JJ None
level NN None
was VBD None
evaluated VBN None
by IN None
bispectral JJ None
index NN None
( ( None
BIS NNP None
) ) None
monitoring NN None
. . None
we PRP None
178 CD Size
patients NNS None
patients NNS None
after IN None
ESD NNP None
-DOCSTART- -X- N

patients NNS None
with IN None
metabolic JJ None
syndrome JJ None
receiving VBG None
low-dose JJ None
aspirin NN None
. . None
Patients NNS None
who WP None
had VBD None
metabolic JJ None
syndrome NN None
-DOCSTART- -X- N

patients NNS None
with IN None
cancer NN Condition
. . None
opioid-tolerant JJ None
patients NNS None
with IN None
cancer NN None
. . None
conducted VBN None
in IN None
opioid-tolerant JJ None
male NN Sex
and CC Sex
female JJ Sex
patients NNS None
( ( None
aged VBN None
> NN Age
or CC Age
=17 CD Age
years NNS None
) ) None
with IN None
BTcP NNP None
. . None
131 CD Size
patients NNS None
entered VBD None
the DT None
titration NN None
phase NN None
, , None
of IN None
whom WP None
61 CD Size
were VBD None
included VBN None
in IN None
the DT None
primary JJ None
efficacy NN None
analysis NN None
. . None
opioid-tolerant JJ None
patients NNS None
with IN None
cancer NN None
. . None
-DOCSTART- -X- N

737 CD None
patients NNS None
with IN None
aggressive JJ None
malignant JJ None
lymphoma NN None
. . None
From IN None
July NNP None
1984 CD None
to TO None
September NNP None
1987 CD None
, , None
737 CD None
patients NNS None
with IN None
aggressive JJ None
malignant JJ None
lymphoma NN None
( ( None
ML NNP None
) ) None
Four CD None
hundred VBD None
forty-two JJ None
patients NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
superficial JJ Condition
bladder NN Condition
tumors NNS Condition
. . None
superficial JJ Condition
bladder NN Condition
carcinoma NNS Condition
A NNP None
total NN None
of IN None
301 CD Size
patients NNS None
underwent JJ None
transurethral JJ Condition
resection NN Condition
of IN None
bladder NN Condition
tumors NNS Condition
with IN None
white JJ None
light NN None
or CC None
fluorescence NN None
diagnosis NN None
. . None
A DT None
total NN None
of IN None
191 CD Size
patients NNS None
with IN None
superficial JJ Condition
bladder NN Condition
carcinoma NN Condition
were VBD None
available JJ None
-DOCSTART- -X- N

low-fat JJ None
( ( None
20 CD None
% NN None
energy NN None
) ) None
dietary JJ None
pattern NN None
Data NNP None
from IN None
13,277 CD Size
postmenopausal JJ Condition
women NNS Sex
randomly RB None
assigned VBN None
to TO None
the DT None
low-fat JJ None
intervention NN None
arm NN None
of IN None
the DT None
Women NNP None
's POS None
Health NNP None
Initiative NNP None
Dietary NNP None
Modification NNP None
Trial NNP None
. . None
Year NNP None
1 CD None
program NN None
participation NN None
( ( None
degree NN None
of IN None
attending VBG None
group NN None
sessions NNS None
and CC None
submitting VBG None
fat JJ None
scores NNS None
) ) None
and CC None
adherence NN None
to TO None
the DT None
low-fat JJ None
dietary JJ None
pattern NN None
-DOCSTART- -X- N

type NN Condition
2 CD Condition
diabetes NNS Condition
. . None
patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
type NN Condition
2 CD Condition
diabetic JJ Condition
patients NNS None
eight CD Size
patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
who WP None
were VBD None
being VBG None
treated VBN None
with IN None
oral JJ None
glucose-lowering JJ None
agents NNS None
. . None
type NN Condition
2 CD Condition
diabetic JJ Condition
patients NNS None
atherosclerosis NN Condition
in IN None
type NN Condition
2 CD Condition
diabetic JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

Japanese JJ None
adult NN Age
healthy JJ Condition
subjects NNS None
: : None
Japanese JJ None
healthy JJ Condition
subjects NNS Condition
. . None
Forty-eight JJ Size
Japanese JJ None
healthy JJ Condition
subjects NNS Condition
( ( None
males NNS Sex
24 CD Size
; : None
females NNS Sex
24 CD Size
) ) None
single-center JJ None
, , None
double-blind JJ None
Japanese JJ None
subjects NNS None
; : None
-DOCSTART- -X- N

exposure NN Condition
to TO Condition
acid VB Condition
fog NN Condition
: : Condition
seven CD None
healthy JJ None
young JJ None
men NNS None
-DOCSTART- -X- N

of IN None
ulcerative JJ None
colitis NN None
. . None
Overall NNP None
, , None
826 CD None
patients NNS None
were VBD None
randomized VBN None
and CC None
dosed VBN None
. . None
-DOCSTART- -X- N

46 CD Size
patients NNS None
participating VBG None
in IN None
a DT None
current JJ None
trial NN None
of IN None
therapy NN None
for IN None
osteoporosis NN Condition
30 CD Size
patients NNS None
with IN None
follow-up JJ None
data NNS None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ None
proximal JJ None
plantar NN None
fasciitis NN None
: : None
chronically RB None
painful JJ None
proximal JJ None
plantar NN None
fasciitis NN None
Forty-seven JJ None
patients NNS None
( ( None
49 CD None
feet NNS None
) ) None
with IN None
a DT None
previously RB None
unsuccessful JJ None
nonsurgical JJ None
treatment NN None
of IN None
at IN None
least JJS None
6 CD None
months NNS None
were VBD None
randomized VBN None
to TO None
two CD None
groups NNS None
. . None
Group NNP None
1 CD None
( ( None
25 CD None
heels NNS None
) ) None
group NN None
2 CD None
( ( None
24 CD None
heels NNS None
) ) None
-DOCSTART- -X- N

recipients NNS None
of IN None
extended JJ None
criteria NNS None
donor JJ None
kidneys NNS None
. . None
Patients NNS None
in IN None
the DT None
BENEFIT-EXT NNP None
study NN None
received VBD None
extended JJ None
criteria NNS None
donor JJ None
kidneys NNS None
Patients NNS None
who WP None
remained VBD None
on IN None
assigned JJ None
therapy NN None
through IN None
year NN None
3 CD None
were VBD None
eligible JJ None
to TO None
enter VB None
a DT None
long-term JJ None
extension NN None
( ( None
LTE NNP None
) ) None
study NN None
. . None
Three CD None
hundred VBD None
four CD None
patients NNS None
entered VBD None
the DT None
LTE NNP None
( ( None
n JJ None
= $ None
104 CD None
MI NNP None
; : None
n CC None
= $ None
113 CD None
LI NNP None
; : None
n CC None
= $ None
87 CD None
CsA NNP None
) ) None
, , None
and CC None
260 CD None
continued VBD None
treatment NN None
through IN None
year NN None
5 CD None
( ( None
n JJ None
= $ None
69 CD None
CsA NNP None
) ) None
. . None
Twenty CD None
patients NNS None
who WP None
were VBD None
seronegative JJ None
for IN None
Epstein-Barr NNP None
virus NN None
( ( None
EBV NNP None
( ( None
- : None
) ) None
) ) None
at IN None
transplantation NN None
-DOCSTART- -X- N

children NNS Age
with IN None
autism NN Condition
autism NN None
in IN None
children NNS None
. . None
Children NNP None
with IN None
core NN Condition
autism NN Condition
( ( None
aged VBN None
2 CD Age
years NNS Age
to TO Age
4 CD Age
years NNS Age
and CC Age
11 CD Age
months NNS Age
) ) None
were VBD None
randomly RB None
assigned VBN None
in IN None
a DT None
one-to-one JJ None
ratio NN None
to TO None
a DT None
parent-mediated JJ None
communication-focused JJ None
was VBD None
by IN None
use NN None
of IN None
minimisation NN None
of IN None
probability NN None
in IN None
the DT None
marginal JJ None
distribution NN None
of IN None
treatment NN None
centre NN None
, , None
age NN None
( ( None
< JJ None
/=42 NNP None
months NNS None
or CC None
> $ None
42 CD None
months NNS None
) ) None
, , None
and CC None
autism NN None
severity NN None
( ( None
Autism NNP None
Diagnostic NNP None
Observation NNP None
Schedule-Generic NNP None
[ NNP None
ADOS-G NNP None
] NNP None
algorithm VBZ None
score RB None
12-17 JJ None
or CC None
18-24 JJ None
) ) None
parent-child JJ None
152 CD Size
children NNS None
were VBD None
recruited VBN None
. . None
77 CD Size
were VBD None
assigned VBN None
to TO None
PACT NNP None
( ( None
London NNP None
[ NNP None
n=26 MD None
] VB None
, , None
Manchester NNP None
[ NNP None
n=26 MD None
] VB None
, , None
and CC None
Newcastle NNP None
[ NNP None
n=25 FW None
] NNP None
) ) None
; : None
and CC None
75 CD Size
to TO None
treatment NN None
as IN None
usual JJ None
( ( None
London NNP None
[ NNP None
n=26 MD None
] VB None
, , None
Manchester NNP None
[ NNP None
n=26 MD None
] VB None
, , None
and CC None
Newcastle NNP None
[ NNP None
n=23 FW None
] NNP None
) ) None
. . None
-DOCSTART- -X- N

haemorrhagic JJ Condition
diathesis NN Condition
of IN None
fulminant JJ Condition
hepatic JJ Condition
failure NN Condition
. . None
fulminant JJ Condition
hepatic JJ Condition
failure NN Condition
nine CD Size
patients NNS None
were VBD None
randomly RB None
allocated VBN None
to TO None
treatment NN None
with IN None
either DT None
concentrate NN None
alone RB None
or CC None
concentrate VB None
plus CC None
heparin VB None
. . None
-DOCSTART- -X- N

dialysis NN Condition
patients NNS None
. . None
28 CD Size
patients NNS None
were VBD None
randomized VBN None
to TO None
maintenance NN None
of IN None
Cndi NNP None
at IN None
13.6 CD None
mS/cm NNS None
( ( None
equivalent JJ None
to TO None
135 CD None
mmol/L NN None
of IN None
Na+ NNP None
) ) None
or CC None
serial JJ None
reduction NN None
of IN None
Cndi NNP None
in IN None
steps NNS None
of IN None
0.2 CD None
mS/cm NNS None
, , None
guided VBN None
by IN None
symptoms NNS None
and CC None
blood NN None
pressure NN None
. . None
-DOCSTART- -X- N

rural JJ Condition
family NN Condition
medicine NN None
: : None
December NNP None
2008 CD None
and CC None
April NNP None
2011 CD None
to TO None
improve VB None
CRC NNP None
screening VBG None
in IN None
16 CD None
rural JJ None
family NN None
physician NN None
offices NNS None
. . None
Subjects NNS Condition
due JJ None
for IN None
CRC NNP Condition
screening VBG Condition
This DT None
study NN None
enrolled VBD None
743 CD Size
patients NNS None
. . None
-DOCSTART- -X- N

Coronary NNP Condition
Artery NNP Condition
Bypass NNP Condition
Graft NNP Condition
patients NNS None
: : None
patients NNS None
who WP None
had VBD None
CABG NNP Condition
surgery NN Condition
. . None
CABG NNP Condition
patient NN None
's POS None
convenience NN None
sample NN None
of IN None
first JJ None
time NN None
CABG NNP Condition
patients NNS None
. . None
individuals NNS None
who WP None
received VBD None
education NN None
post-discharge NN None
on IN None
the DT None
outcomes NNS None
. . None
-DOCSTART- -X- N

postsurgical JJ Condition
orthopedic JJ Condition
patients NNS Condition
: : None
postsurgical JJ Condition
orthopedic JJ Condition
patients NNS None
Patients NNPS None
( ( None
N=60 NNP Size
) ) None
admitted VBD None
to TO None
our PRP$ None
department NN None
postorthopedic NN None
surgery NN None
Exclusion NN None
criteria NNS None
were VBD None
age NN None
18 CD Age
years NNS Age
or CC Age
younger JJR Age
and CC Age
90 CD Age
years NNS Age
or CC Age
older JJR Age
, , None
Mini-Mental JJ None
State NNP None
Examination NNP None
score NN None
of IN None
21 CD None
of IN None
30 CD None
or CC None
lower JJR None
, , None
no DT None
ambulating VBG None
order NN None
, , None
advanced JJ None
vision NN None
impairment NN None
, , None
malignancy NN None
, , None
pneumonia NN None
, , None
or CC None
heart NN None
failure NN None
. . None
conventional JJ None
physiotherapy NN None
. . None
postsurgical JJ None
orthopedic JJ None
patients NNS None
. . None
nonneurologic JJ None
patients NNS None
. . None
-DOCSTART- -X- N

laparoscopic NN None
colon NN Condition
cancer NN Condition
operation NN None
One CD Size
hundred VBD Size
sixty-three JJ Size
colon NN Condition
cancer NN Condition
patients NNS None
underwent VBD None
the DT None
traditional JJ None
protocol NN None
and CC None
open JJ None
operation NN None
( ( None
traditional JJ None
open JJ None
group NN None
, , None
n=42 RB Size
) ) None
, , None
the DT None
traditional JJ None
protocol NN None
and CC None
laparoscopic NN None
operation NN None
( ( None
traditional JJ None
laparoscopic NN None
group NN None
, , None
n=40 RB Size
) ) None
, , None
the DT None
FT NNP None
protocol NN None
and CC None
open JJ None
operation NN None
( ( None
FT NNP None
open JJ None
group NN None
, , None
n=41 RB Size
) ) None
, , None
or CC None
the DT None
FT NNP None
protocol NN None
and CC None
laparoscopic NN None
operation NN None
( ( None
FT NNP None
laparoscopic NN None
group NN None
, , None
n=40 RB Size
) ) None
. . None
FT NNP None
laparoscopic NN None
patients NNS None
. . None
-DOCSTART- -X- N

chronic JJ Condition
nonspecific NN Condition
low JJ Condition
back RB Condition
pain NN Condition
patient NN None
] NN None
chronic JJ Condition
nonspecific NN Condition
low JJ Condition
back RB Condition
pain NN Condition
patient NN None
. . None
Three CD Size
hundred VBD Size
and CC Size
five CD Size
cases NNS None
chronic JJ Condition
nonspecific NN Condition
low JJ Condition
back RB Condition
pain NN Condition
patient NN None
-DOCSTART- -X- N

Siriraj NNP None
Asthma NNP Condition
Control NNP None
Siriraj NNP None
Hospital NNP None
. . None
20 CD Size
randomized JJ None
asthmatic JJ Condition
patients NNS None
in IN None
the DT None
clinic NN None
including VBG None
the DT None
record NN None
of IN None
3 CD None
visits NNS None
for IN None
each DT None
subject NN None
. . None
20 CD None
patients NNS None
with IN None
age NN None
29-73 CD Age
years NNS None
Thai NNP None
asthmatic JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

Gastric JJ Condition
ulcer NN Condition
treatment NN None
( ( None
67/86 CD Size
) ) None
patients NNS None
receiving VBG None
6 CD None
micrograms NNS None
EGF NNP None
intravenously RB None
twice RB None
a DT None
week NN None
rat NN None
gastric JJ Condition
ulcers NNS Condition
-DOCSTART- -X- N

patients NNS None
of IN None
noninsulin JJ Condition
dependent JJ Condition
diabetes VBZ Condition
mellitus NN Condition
-- : None
a DT None
50 CD Size
patients NNS None
with IN None
type JJ Condition
2 CD Condition
diabetes NNS Condition
mellitus VBP Condition
in IN Condition
uncontrolled JJ Condition
state NN Condition
Fifty JJ Size
patients NNS None
of IN None
uncontrolled JJ Condition
type NN Condition
2 CD Condition
diabetes NNS Condition
-DOCSTART- -X- N

patients NNS None
with IN None
solid JJ Condition
tumours NNS Condition
. . None
patients NNS None
with IN None
solid JJ Condition
tumours NN Condition
patients NNS None
( ( None
N=61 NNP Size
) ) None
-DOCSTART- -X- N

skin NN Condition
and CC Condition
soft-tissue JJ Condition
infections NNS Condition
. . None
75 CD Size
patients NNS None
received VBD None
teicoplanin JJ None
intravenously RB None
( ( None
38 CD Size
) ) None
or CC None
intramuscularly RB None
( ( None
37 CD Size
, , None
of IN None
which WDT None
16 CD Size
were VBD None
outpatients NNS None
) ) None
62 CD Size
clinically RB None
evaluable JJ None
patients NNS None
-DOCSTART- -X- N

total JJ Condition
hip JJ Condition
replacement NN Condition
: : None
a DT None
randomized JJ None
prospective JJ None
study NN None
. . None
From IN None
2004 CD None
to TO None
2008 CD None
, , None
81 CD Size
patients NNS None
seeking VBG None
elective JJ None
THRs NNP None
were VBD None
randomly RB None
assigned VBN None
into IN None
a DT None
standard JJ None
rehabilitation NN None
group NN None
or CC None
an DT None
early JJ None
rehabilitation NN None
group NN None
. . None
standard JJ None
group NN None
included VBD None
restrictions NNS None
to TO None
avoid VB None
hip NN None
flexion NN None
> VBD None
90 CD None
degrees NNS None
and CC None
avoidance NN None
of IN None
riding VBG None
in IN None
a DT None
car NN None
for IN None
the DT None
first JJ None
postoperative JJ None
month NN None
. . None
The DT None
early JJ None
group NN None
had VBD None
no DT None
flexion NN None
or CC None
car NN None
riding NN None
restrictions NNS None
. . None
Forty-three JJ Size
patients NNS None
were VBD None
in IN None
the DT None
standard JJ None
group NN None
and CC None
38 CD Size
patients NNS None
were VBD None
in IN None
the DT None
early JJ None
group NN None
. . None
no DT None
significant JJ None
demographic JJ None
differences NNS None
between IN None
the DT None
2 CD None
groups NNS None
. . None
-DOCSTART- -X- N

participants NNS None
performed VBD None
a DT None
self-timed JJ None
30 CD None
minute NN None
brisk NN Condition
walk VBP Condition
in IN None
two CD None
different JJ None
environments NNS None
, , None
park NN None
and CC None
urban JJ None
sample NN None
of IN None
40 CD None
healthy JJ None
adults NNS None
was VBD None
recruited VBN None
: : None
16 CD None
males NNS None
, , None
24 CD None
females NNS None
, , None
mean JJ None
age NN None
22.9 CD None
( ( None
5.5 CD None
) ) None
years NNS None
. . None
The DT None
steps/min NN None
. . None
Participants NNS None
accumulated VBD None
-DOCSTART- -X- N

humans NNS None
. . None
eight CD Size
healthy JJ Condition
volunteers NNS None
( ( None
age NN None
= VBZ None
22 CD Age
+/- JJ Age
2 CD Age
y NN None
, , None
body NN None
mass NN None
index NN None
= VBD None
24 CD Condition
+/- JJ Condition
1 CD Condition
kg NN Condition
) ) None
-DOCSTART- -X- N

patients NNS None
with IN None
unilateral JJ Condition
lung NN Condition
pathology NN Condition
. . None
patients NNS None
with IN None
unilateral JJ Condition
lung NN Condition
pathology NN Condition
Thirty-nine JJ Size
patients NNS None
with IN None
unilateral JJ Condition
lung NN Condition
pathology NN Condition
-DOCSTART- -X- N

study NN None
enrolled VBD None
263 CD Size
healthy JJ Condition
smokers NNS Condition
( ( None
M NNP None
( ( None
age NN None
) ) None
= VBZ None
49 CD Age
years NNS Age
) ) None
who WP None
smoked VBD Condition
a DT None
mean NN None
of IN None
24 CD Condition
cigarettes/day NN Condition
, , None
with IN None
a DT None
mean NN None
of IN None
31 CD Condition
pack-years NNS Condition
. . None
-DOCSTART- -X- N

International NNP None
Czech NNP None
and CC None
Slovak NNP None
patients NNS None
with IN None
differentiated JJ Condition
thyroid NN Condition
cancer NN Condition
. . None
Slovak NNP None
patients NNS None
with IN None
differentiated JJ None
thyroid NN None
cancer NN None
in IN None
Slovak NNP None
and CC None
Czech NNP None
hospitals NNS None
. . None
From NNP None
September NNP None
1991 CD None
to TO None
October NNP None
2005 CD None
in IN None
the DT None
Department NNP None
of IN None
Nuclear NNP None
Medicine NNP None
in IN None
Ostrava NNP None
357 CD Size
patients NNS None
from IN None
the DT None
Slovak NNP None
Republic NNP None
with IN None
differentiated VBN Condition
thyroid NN Condition
cancers NNS Condition
( ( None
follicular JJ Condition
and CC Condition
papillary JJ Condition
) ) None
underwent NN None
complex JJ None
therapy NN None
. . None
They PRP None
were VBD None
diagnosed VBN None
and CC None
operated VBN None
due JJ None
to TO None
the DT None
cancer NN None
( ( None
near-total JJ Condition
thyroidectomy NN Condition
and CC None
removal NN Condition
of IN Condition
lymph JJ Condition
node JJ Condition
metastases NNS Condition
) ) None
in IN None
Slovak NNP None
hospitals NNS None
. . None
Then RB None
they PRP None
were VBD None
sent VBN None
to TO None
the DT None
Department NNP None
of IN None
Nuclear NNP None
Medicine NNP None
in IN None
Ostrava NNP None
in IN None
the DT None
Czech NNP None
Republic NNP None
. . None
Slovak NNP None
Republic NNP None
, , None
in IN None
the DT None
University NNP None
Hospital NNP None
in IN None
Martin NNP None
. . None
-DOCSTART- -X- N

559 CD Size
patients NNS None
after IN None
tumour JJ Condition
excision NN Condition
and CC None
radiotherapy NN Condition
for IN None
early JJ Condition
breast NN Condition
cancer NN Condition
-DOCSTART- -X- N

atrial JJ Condition
fibrillation NN Condition
: : None
patients NNS None
with IN None
AF NNP None
. . None
Patients NNS None
with IN None
persistent JJ Condition
AF NNP Condition
or CC None
AF NNP Condition
induced VBD Condition
during IN None
a DT None
routine JJ None
electrophysiology NN Condition
study NN Condition
( ( None
EPS NNP None
) ) None
patients NNS None
with IN None
induced JJ None
AF NNP None
AF NNP None
in IN None
patients NNS None
-DOCSTART- -X- N

new JJ Condition
mothers NNS Condition
' POS None
low-income JJ None
, , None
first-time JJ None
mothers NNS None
' POS None
safety NN None
practices NNS None
during IN None
their PRP$ None
child NN None
's POS None
first JJ None
18 CD None
months NNS None
. . None
Primiparous JJ Condition
women NNS Sex
( ( None
n JJ None
= NNP None
167 CD Size
) ) None
-DOCSTART- -X- N

nonresectable JJ Condition
rectal JJ Condition
cancer NN Condition
: : None
locally RB Condition
advanced JJ Condition
rectal JJ Condition
cancer NN Condition
Patients NNP None
( ( None
N NNP None
= NNP None
207 CD None
) ) None
with IN None
nonresectable JJ None
rectal JJ None
cancer NN None
were VBD None
randomized VBN None
to TO None
preoperative VB None
CRT NNP None
or CC None
RT NNP None
( ( None
2 CD None
Gy NNP None
? . None
25 CD None
? . None
5-fluorouracil/leucovorin JJ None
) ) None
. . None
the DT None
105 CD None
patients NNS None
alive JJ None
in IN None
Norway NNP None
and CC None
Sweden NNP None
after IN None
4 CD None
to TO None
12 CD None
years NNS None
of IN None
follow-up NN None
, , None
78 CD None
( ( None
74 CD None
% NN None
) ) None
responded VBD None
44 CD None
patients NNS None
in IN None
the DT None
CRT NNP None
group NN None
, , None
for IN None
locally RB None
advanced JJ None
rectal JJ None
cancer NN None
. . None
-DOCSTART- -X- N

data NNS None
from IN None
the DT None
Physicians NNPS None
' POS None
Health NNP None
Study NNP None
aspirin JJ Condition
users NNS Condition
22071 CD Size
U.S. NNP None
male JJ Sex
physicians NNS None
. . None
aspirin JJ None
arm NN None
-DOCSTART- -X- N

high-risk JJ None
patients NNS None
with IN None
recent JJ None
myocardial JJ Condition
infarction NN Condition
: : None
stable JJ None
patients NNS None
with IN None
low JJ Condition
ejection NN Condition
fraction NN Condition
late RB None
after IN None
myocardial JJ None
infarction NN None
Outpatients NNS None
with IN None
recent JJ None
( ( None
6 CD None
to TO None
40 CD None
days NNS None
) ) None
acute VBP Condition
myocardial JJ Condition
infarction NN Condition
, , None
left VBD Condition
ventricular JJ Condition
dysfunction NN Condition
( ( Condition
ejection JJ Condition
fraction NN Condition
< VBD Condition
35 CD Condition
% NN Condition
) ) None
, , None
and CC None
low JJ Condition
heart NN Condition
rate NN Condition
variability NN Condition
ICD NNP Condition
patients NNS None
ICD NNP Condition
patients NNS None
patients NNS None
patients NNS None
receiving VBG None
ICDs NNP Condition
early RB None
after IN None
myocardial JJ Condition
infarction NN Condition
-DOCSTART- -X- N

severe JJ None
neurological JJ None
manifestations NNS None
in IN None
systemic JJ None
lupus NN None
erythematosus NN None
. . None
Severe NNP None
neurological JJ None
involvement NN None
in IN None
systemic JJ None
lupus NN None
erythematosus NN None
( ( None
NPSLE NNP None
) ) None
two CD None
tertiary JJ None
care NN None
centres NNS None
of IN None
patients NNS None
with IN None
SLE NNP None
according VBG None
to TO None
the DT None
ACR NNP None
criteria NNS None
, , None
with IN None
incident NN None
( ( None
no DT None
more JJR None
than IN None
15 CD None
days NNS None
) ) None
onset NN None
of IN None
severe JJ None
NP NNP None
manifestations NNS None
such JJ None
as IN None
seizures NNS None
, , None
optic JJ None
neuritis NN None
, , None
peripheral JJ None
or CC None
cranial JJ None
neuropathy NN None
, , None
coma NN None
, , None
brainstem NN None
disease NN None
, , None
or CC None
transverse JJ None
myelitis NN None
. . None
32 CD None
patients NNS None
studied VBN None
-DOCSTART- -X- N

secondary JJ Condition
hyperparathyroidism NN Condition
in IN None
stages NNS Condition
3 CD Condition
and CC Condition
4 CD Condition
CKD NNP Condition
. . None
secondary JJ None
hyperparathyroidism NN None
( ( None
SHPT NNP Condition
) ) None
in IN None
patients NNS None
with IN None
chronic JJ Condition
kidney NN Condition
disease NN Condition
( ( None
CKD NNP Condition
) ) None
stage NN Condition
5 CD Condition
. . None
Three NNP None
randomized VBD None
, , None
placebo-controlled JJ None
, , None
phase-3 JJ None
trials NNS None
were VBD None
conducted VBN None
in IN None
patients NNS None
with IN None
stages NNS None
3 CD None
and CC None
4 CD None
CKD NNP None
with IN None
SHPT NNP None
. . None
Enrollment NNP None
criteria NNS None
included VBD None
an DT None
estimated VBN None
glomerular JJ None
filtration NN None
rate NN None
between IN None
15 CD None
and CC None
60 CD None
mL/min/1.73 NN None
m2 NN None
( ( None
0.25 CD None
and CC None
1.00 CD None
mL/s/1.73 NNS None
m2 NN None
) ) None
, , None
an DT None
average NN None
of IN None
2 CD None
consecutive JJ None
intact JJ None
parathyroid NN None
hormone NN None
( ( None
iPTH NN None
) ) None
levels NNS None
greater JJR None
than IN None
150 CD None
pg/mL NN None
( ( None
ng/L JJ None
) ) None
, , None
2 CD None
consecutive JJ None
serum NN None
calcium NN None
levels NNS None
between IN None
8.0 CD None
and CC None
10.0 CD None
mg/dL NN None
( ( None
2.00 CD None
and CC None
2.50 CD None
mmol/L NN None
) ) None
, , None
and CC None
2 CD None
consecutive JJ None
serum NN None
phosphorus NN None
levels NNS None
of IN None
5.2 CD None
mg/dL NN None
or CC None
less JJR None
( ( None
< NN None
or CC None
= $ None
1.68 CD None
mmol/L NN None
) ) None
. . None
Two CD Size
hundred VBD Size
twenty NN Size
patients NNS None
participated VBD None
( ( None
n JJ None
= NN None
107 CD Size
, , None
paricalcitol NN None
; : None
n CC None
= $ None
113 CD Size
, , None
placebo NN None
) ) None
. . None
-DOCSTART- -X- N

head JJ Condition
injury NN Condition
Eight NNP Size
hundred VBD Size
sixty-one JJ Size
patients NNS None
with IN None
severe JJ Condition
traumatic JJ Condition
brain NN Condition
injury NN Condition
who WP None
were VBD None
admitted VBN None
to TO None
86 CD None
centers NNS None
-DOCSTART- -X- N

of IN None
healthy JJ None
adults NNS None
. . None
74 CD None
healthy JJ None
men NNS None
and CC None
women NNS None
. . None
-DOCSTART- -X- N

uterine JJ Condition
myoma NN Condition
regression NN Condition
. . None
This DT None
study NN None
took VBD None
place NN None
in IN None
the DT None
Department NNP None
of IN None
Obstetrics NNP None
and CC None
Gynecology NNP None
of IN None
Tabriz NNP None
University NNP None
of IN None
Medical NNP None
Sciences NNPS None
, , None
Tabriz NNP None
, , None
Iran NNP None
from IN None
July NNP None
2004 CD None
to TO None
December NNP None
2005 CD None
. . None
Fifty NNP Condition
women NNS Condition
with IN None
uterine JJ Condition
myoma NN Condition
, , None
who WP None
met VBD None
the DT None
criteria NNS None
of IN None
the DT None
study NN None
thoroughly RB None
-DOCSTART- -X- N

school-aged JJ Age
children NNS Age
school-aged JJ None
children NNS None
30 CD Size
healthy JJ Condition
children NNS None
children NNS Age
children NNS None
-DOCSTART- -X- N

patients NNS None
on IN None
thyroid JJ Condition
hormone NN Condition
replacement NN Condition
. . None
697 CD Size
patients NNS None
on IN None
thyroid JJ None
hormone NN None
replacement NN None
therapy NN None
at IN None
entry NN None
to TO None
a DT None
randomized VBN None
, , None
controlled VBD None
trial NN None
of IN None
combined JJ None
T NNP None
( ( None
4 CD None
) ) None
and CC None
T NNP None
( ( None
3 CD None
) ) None
replacement NN None
therapy NN None
. . None
All DT None
patients NNS None
were VBD None
on IN None
100 CD None
mug NN None
or CC None
more JJR None
T NNP None
( ( None
4 CD None
) ) None
. . None
treated JJ None
hypothyroid NN Condition
patients NNS None
-DOCSTART- -X- N

Parkinson NNP Condition
's POS Condition
disease NN Condition
: : None
Forty-five NNP Size
women NNS Sex
and CC Sex
men NNS Sex
, , None
aged VBN None
50-79 CD Age
years NNS None
, , None
were VBD None
recruited VBN None
. . None
Twenty-nine NN Size
of IN None
them PRP None
were VBD None
blindly RB None
randomised VBN None
to TO None
tactile VB None
massage NN None
( ( None
TM NNP None
) ) None
and CC None
16 CD Size
of IN None
them PRP None
to TO None
the DT None
control NN None
group NN None
, , None
rest NN None
to TO None
music NN None
( ( None
RTM NNP None
) ) None
-DOCSTART- -X- N

gingival JJ None
health NN None
among IN None
adults NNS Age
with IN None
systemic JJ Condition
sclerosis NN Condition
. . None
among IN None
adults NNS Age
with IN None
systemic JJ Condition
sclerosis NN Condition
( ( None
SSc NNP Condition
) ) None
. . None
Forty-eight JJ Size
patients NNS None
with IN None
SSc NNP Condition
health NN None
in IN None
adults NNS None
with IN None
SSc NNP None
educating VBG None
patients NNS None
with IN None
SSc NNP None
-DOCSTART- -X- N

threshold JJ None
retinopathy NN Condition
of IN Condition
prematurity NN Condition
. . None
retinopathy NN Condition
of IN Condition
prematurity NN Condition
( ( None
ROP NNP Condition
) ) None
Patients NNPS None
Nineteen JJ Size
infants NNS None
( ( None
33 CD Size
eyes NNS None
) ) None
were VBD None
treated VBN None
, , None
ranging VBG None
from IN None
485 CD None
to TO None
863 CD None
g NNS None
birth JJ None
weight NN None
( ( None
23 CD None
to TO None
27 CD None
weeks NNS None
gestational JJ None
age NN None
) ) None
; : None
18 CD Size
patients NNS None
( ( None
32 CD Size
eyes NNS None
) ) None
Four CD Size
patients NNS None
( ( None
8 CD Size
eyes NNS None
) ) None
had VBD None
bilateral JJ None
zone CD None
1 CD None
disease NN None
. . None
Postconceptional JJ None
age NN None
was VBD None
36 CD Age
to TO Age
45 CD Age
weeks NNS None
at IN None
the DT None
time NN None
of IN None
treatment NN None
. . None
-DOCSTART- -X- N

gastric JJ Condition
cancer NN Condition
in IN None
gastric JJ Condition
cardia NN Condition
cancer NN Condition
( ( None
GCC NNP Condition
) ) None
and CC None
gastric JJ Condition
noncardia NN Condition
cancer NN Condition
( ( None
GNCC NNP Condition
) ) None
341 CD Size
incident JJ None
gastric JJ None
cancer NN None
cases NNS None
( ( None
86 CD None
cardia NN None
, , None
172 CD None
noncardia NN None
, , None
and CC None
83 CD None
nonspecified VBN None
) ) None
, , None
accrued VBN None
during IN None
22 CD None
years NNS None
of IN None
follow-up NN None
, , None
and CC None
341 CD Size
individually RB None
matched VBN None
controls NNS None
. . None
GNCC NNP None
-DOCSTART- -X- N

stapled JJ None
versus NN None
open JJ None
hemorrhoidectomy NN Condition
. . None
hemorrhoids NNS Condition
Milligan NNP None
Morgan NNP None
hemorrhoidectomy NN None
. . None
84 CD Size
patients NNS None
were VBD None
randomly RB None
allocated VBN None
to TO None
the DT None
stapled VBN None
( ( None
n JJ None
= NNP None
42 CD Size
) ) None
or CC None
open JJ None
group NN None
( ( None
n JJ None
= NNP None
42 CD Size
) ) None
. . None
All DT None
patients NNS None
were VBD None
operated VBN None
on IN None
under IN None
spinal JJ None
anesthesia NN None
. . None
mean JJ None
age NN None
of IN None
patients NNS None
was VBD None
46.02 CD Age
years NNS None
( ( None
SD NNP None
, , None
12.33 CD None
) ) None
in IN None
the DT None
stapled JJ None
group NN None
and CC None
48.64 CD Age
years NNS None
( ( None
14.57 CD None
) ) None
in IN None
the DT None
open JJ None
group NN None
. . None
Grade NNP Condition
III NNP Condition
or CC Condition
IV NNP Condition
hemorrhoids NNS Condition
were VBD None
more JJR None
common JJ None
in IN None
men NNS None
( ( None
ie NN None
, , None
80.9 CD None
% NN None
and CC None
85.7 CD None
% NN None
in IN None
the DT None
stapled JJ None
and CC None
open JJ None
group NN None
, , None
respectively RB None
) ) None
. . None
grade NN Condition
III NNP Condition
and CC Condition
grade VBD Condition
IV NNP Condition
hemorrhoids NNS Condition
. . None
-DOCSTART- -X- N

postmenopausal JJ Condition
women NNS Sex
. . None
normotensive JJ Condition
postmenopausal NN Condition
women NNS Sex
receiving VBG None
a DT None
fixed JJ None
mid-range JJ None
daily JJ None
dose NN None
of IN None
conjugated JJ None
equine NN None
oestrogen NN None
( ( None
CEE NNP None
) ) None
. . None
Twenty NNP Size
normotensive JJ Condition
postmenopausal NN Condition
women NNS Sex
( ( None
median JJ None
age NN None
53 CD Age
years NNS None
) ) None
-DOCSTART- -X- N

post-thoracotomy JJ Condition
20 CD Size
patients NNS None
undergoing JJ None
lateral JJ Condition
thoracotomy NN Condition
for IN None
lung NN Condition
resection NN Condition
-DOCSTART- -X- N

influenza JJ Condition
vaccination NN Condition
in IN None
elderly JJ Age
. . None
influenza VB Condition
vaccination NN Condition
in IN None
elderly JJ Age
60 CD Size
institutionalized JJ None
volunteers NNS None
aged VBN None
65-85 CD Age
years NNS None
-DOCSTART- -X- N

obese JJ Condition
patients NNS Condition
Sixty NNP Condition
obese JJ Condition
women NNS Condition
were VBD Condition
included VBN Condition
in IN Condition
the DT Condition
study NN Condition
. . Condition
were VBD None
divided VBN None
into IN None
2 CD None
equal JJ None
groups-the JJ None
-DOCSTART- -X- N

12 CD None
healthy JJ None
male NN None
volunteers NNS None
Six CD None
participants NNS None
-DOCSTART- -X- N

knee NN Condition
joint JJ Condition
osteoarthritis NN Condition
: : None
knee NN Condition
osteoarthritis NN Condition
140 CD Size
community NN None
volunteers NNS None
with IN None
knee NN Condition
osteoarthritis NN Condition
participated VBD None
and CC None
119 CD Size
completed VBD None
the DT None
trial NN None
. . None
physiotherapy NN None
and CC None
placebo NN None
groups NNS None
-DOCSTART- -X- N

chronic JJ Condition
, , None
non-healing JJ Condition
ulcers NNS Condition
of IN None
the DT None
lower JJR Condition
limb NN Condition
in IN None
patients NNS None
with IN None
diabetes NNS Condition
mellitus NNS Condition
: : None
diabetic JJ Condition
ulcers NNS Condition
. . None
patients NNS None
with IN None
diabetes NNS None
mellitus NNS None
and CC None
chronic JJ Condition
ulcers NNS Condition
of IN None
the DT None
lower JJR Condition
limb NN Condition
. . None
One CD Size
hundred CD Size
and CC Size
eighteen JJ Size
( ( None
59 CD Size
patients NNS None
per IN None
arm NN None
) ) None
patients NNS None
with IN None
non-healing JJ Condition
diabetic JJ Condition
ulcers NNS Condition
of IN None
the DT None
lower JJR Condition
limb NN Condition
, , None
referred VBD None
to TO None
the DT None
Judy NNP None
Dan NNP None
Research NNP None
and CC None
Treatment NNP None
Centre NNP None
are VBP None
being VBG None
recruited VBN None
if IN None
they PRP None
are VBP None
at IN None
least JJS None
18 CD Age
years NNS None
of IN None
age NN None
, , None
have VBP None
either DT None
Type NNP Condition
1 CD Condition
or CC Condition
2 CD Condition
diabetes NNS Condition
with IN None
a DT None
Wagner NNP None
grading NN None
of IN None
foot NN None
lesions NNS None
2 CD None
, , None
3 CD None
or CC None
4 CD None
on IN None
lower JJR None
limb NN None
not RB None
healing VBG None
for IN None
at IN None
least JJS None
4 CD None
weeks NNS None
. . None
non-healing JJ None
ulcers NNS None
of IN None
the DT None
lower JJR None
limb NN None
. . None
diabetic JJ None
patients NNS None
. . None
-DOCSTART- -X- N

obstetric JJ Condition
patients NNS None
with IN None
accidental JJ Condition
dural JJ Condition
puncture NN Condition
-- : None
a DT None
obstetric JJ Condition
patients NNS None
experiencing VBG None
a DT None
severe JJ Condition
post-dural JJ Condition
puncture NN Condition
headache NN Condition
. . None
Patients NNS None
who WP None
sustained VBD None
an DT None
accidental JJ Condition
dural JJ Condition
puncture NN Condition
during IN None
establishment NN None
of IN None
epidural JJ Condition
analgesia NN Condition
during IN None
labour NN Condition
or CC None
at IN None
caesarean JJ Condition
delivery NN None
Eleven NNP Size
of IN None
60 CD Size
( ( None
18.3 CD None
% NN None
) ) None
patients NNS None
39 CD Size
of IN None
49 CD Size
( ( None
79.6 CD None
% NN None
) ) None
obstetric JJ Condition
patients NNS None
. . None
-DOCSTART- -X- N

head NN Condition
and CC Condition
neck NN Condition
cancer NN Condition
: : None
Between IN None
December NNP None
1982 CD None
and CC None
October NNP None
1986 CD None
, , None
131 CD Size
patients NNS None
with IN None
stage JJ Condition
II-III-IV NNP Condition
squamous JJ Condition
cell NN Condition
carcinoma NN Condition
of IN None
the DT None
oropharynx NN Condition
or CC None
oral JJ Condition
cavity NN Condition
A DT None
total NN None
of IN None
116 CD Size
patients NNS None
were VBD None
evaluable JJ None
. . None
-DOCSTART- -X- N

cardiac JJ Condition
arrhythmias NN Condition
in IN Condition
African-American JJ Condition
men NNS Condition
with IN Condition
systemic JJ Condition
hypertension NN Condition
and CC Condition
moderate VB Condition
to TO Condition
severe VB Condition
left JJ Condition
ventricular JJ Condition
hypertrophy NN Condition
. . None
45 CD None
hypertensive JJ None
African-American JJ None
men NNS None
with IN None
moderate JJ None
to TO None
severe VB None
left VBN None
ventricular JJ None
( ( None
LV NNP None
) ) None
hypertrophy NN None
. . None
subgroup NN None
of IN None
24 CD None
patients NNS None
. . None
hypertensive JJ None
African-American JJ None
men NNS None
with IN None
moderate JJ None
to TO None
severe VB None
LV NNP None
hypertrophy NN None
-DOCSTART- -X- N

advanced JJ None
laryngeal NN None
and CC None
hypopharyngeal NN None
squamous JJ None
carcinoma NN None
. . None
Two CD None
hundred VBD None
and CC None
twelve JJ None
patients NNS None
with IN None
previously RB Condition
untreated VBN Condition
advanced JJ Condition
squamous JJ Condition
carcinoma NN Condition
of IN Condition
the DT Condition
larynx NN Condition
or CC Condition
hypopharynx NN Condition
Two CD None
hundred VBD None
and CC None
nine CD None
of IN None
the DT None
212 CD None
patients NNS None
randomized VBN None
were VBD None
included VBN None
in IN None
the DT None
analyses NNS None
. . None
-DOCSTART- -X- N

methadone-maintained JJ None
cocaine NN None
abusers NNS None
patients NNS None
in IN None
methadone JJ None
maintenance NN None
. . None
methadone-maintained JJ None
, , None
cocaine-dependent JJ None
patients NNS None
( ( None
N NNP None
= NNP None
193 CD None
) ) None
with IN None
and CC None
without IN None
concurrent JJ None
AD NNP None
Patients NNS None
with IN None
and CC None
without IN None
concurrent JJ None
AD NNP None
cocaine-using JJ None
methadone NN None
patients NNS None
-DOCSTART- -X- N

4159 CD Size
patients NNS None
with IN None
myocardial JJ None
infarction NN None
and CC None
average JJ None
LDL NNP None
concentrations NNS None
at IN None
baseline NN None
( ( None
115 CD None
to TO None
174 CD None
mg/dL NNS None
, , None
mean VBP None
139 CD None
mg/dL NN None
) ) None
. . None
patients NNS None
who WP None
had VBD None
either CC None
a DT None
myocardial JJ Condition
infarction NN Condition
or CC None
coronary JJ Condition
death NN Condition
( ( None
cases NNS None
, , None
n=418 NN Size
) ) None
patients NNS None
who WP None
did VBD None
not RB None
have VB None
a DT None
cardiovascular JJ None
event NN None
( ( None
control NN None
subjects VBZ None
, , None
n=370 NN Size
) ) None
-DOCSTART- -X- N

patients NNS None
with IN None
chronic JJ Condition
hepatitis NN Condition
C NNP Condition
treated VBD None
with IN None
interferon-alpha JJ None
and CC None
ribavirin NN None
: : None
patients NNS None
with IN None
chronic JJ None
hepatitis NN None
C NNP None
during IN None
and CC None
after IN None
treatment NN None
with IN None
interferon-alpha JJ None
( ( None
IFN-alpha NNP None
) ) None
and CC None
ribavirin NN None
. . None
previously RB None
untreated JJ None
patients NNS None
with IN None
chronic JJ Condition
hepatitis NN Condition
C NNP Condition
patients NNS None
in IN None
the DT None
control NN None
and CC None
the DT None
amantadine NN None
group NN None
. . None
-DOCSTART- -X- N

alcohol NN Condition
withdrawal NN Condition
syndrome NN Condition
in IN None
a DT None
medical JJ None
intensive JJ None
care NN None
unit NN None
: : None
alcohol NN Condition
withdrawal NN Condition
syndrome NN Condition
( ( None
AWS NNP Condition
) ) None
. . None
Twenty-six NNP Size
alcoholic JJ None
patients NNS None
with IN None
severe JJ None
AWS NNP None
and CC None
concomitant JJ None
medical JJ None
diseases NNS None
were VBD None
randomally RB None
enrolled VBN None
in IN None
the DT None
study NN None
. . None
-DOCSTART- -X- N

Hypertensive JJ Condition
patients NNS None
Subjects NNS None
with IN None
a DT None
difference NN None
of IN None
> NN None
or CC None
= $ None
20 CD None
mm NN None
Hg NNP None
systolic NN None
or CC None
> NN None
or CC None
= $ None
10 CD None
mm NN None
Hg NNP None
diastolic VBZ None
BP NNP None
between IN None
CBP NNP None
and CC None
awake VB None
ABP NNP None
or CC None
CBP NNP None
and CC None
HBP NNP None
A DT None
total NN None
of IN None
189 CD Size
patients NNS None
completed VBD None
the DT None
study NN None
( ( None
79 CD Size
on IN None
stable JJ None
antihypertensive JJ None
treatment NN None
) ) None
. . None
-DOCSTART- -X- N

patients NNS None
with IN None
Parkinson NNP Condition
's POS Condition
disease NN Condition
. . None
12 CD Size
patients NNS None
with IN None
Parkinson NNP Condition
's POS Condition
disease NN Condition
and CC None
motor NN Condition
fluctuations NNS Condition
-DOCSTART- -X- N

520 CD None
patients NNS None
with IN None
osteoarthritis NN None
who WP None
underwent VBD None
computer-navigated JJ None
total JJ None
knee NN None
arthroplasty NN None
for IN None
one CD None
knee NN None
and CC None
conventional JJ None
total JJ None
knee NN None
arthroplasty NN None
for IN None
the DT None
other JJ None
. . None
were VBD None
452 CD None
women NNS None
( ( None
904 CD None
knees NNS None
) ) None
and CC None
sixty-eight JJ None
men NNS None
( ( None
136 CD None
knees NNS None
) ) None
with IN None
a DT None
mean JJ None
age NN None
of IN None
sixty-eight JJ None
years NNS None
( ( None
range NN None
, , None
forty-nine JJ None
to TO None
eighty-eight JJ None
years NNS None
) ) None
at IN None
the DT None
time NN None
of IN None
the DT None
index NN None
arthroplasty NN None
. . None
the DT None
knees NNS None
that WDT None
underwent VBD None
computer-navigated JJ None
total JJ None
knee NN None
arthroplasty NN None
and CC None
those DT None
that WDT None
underwent JJ None
conventional JJ None
total JJ None
knee NN None
arthroplasty NN None
. . None
